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Abstract 
Objectives: Compared with other cancers, patients with lung cancer have higher 
prevalence of co-morbidity associated with advanced age and smoking. The objective 
of the present study was to investigate the prevalence of co-morbidity among Chinese 
lung cancer patients in Hong Kong, and to examine the impact of co-morbidity on 
lung cancer survival. 
Methodology: Subjects included in this retrospective cohort study were 1326 primary 
lung cancer incident cases, who had been enrolled in 2 case-control studies regarding 
the association between occupational exposure and smoking with lung cancer among 
males, as well as the association of cooking fumes with lung cancer among females 
between July 2002 and August 2006. All lung cancer patients were follow-up to 
December 2008 to determine the vital status. Detailed information of co-morbidity at 
the time of diagnosis of lung cancer was collected mainly from medical records. 
Co-morbidity indices were referred to co-morbidity count, major types of 
co-morbidity in different systems or organs, and individual specific co-morbid 
condition or disease. Multiple Cox's proportional hazard model were performed to 
evaluate the impacts of each co-morbidity index on the survival of all lung cancer 
patients and its two major histological subtypes (non-small cell lung cancer [NSCLC] 
and small cell lung cancer [SCLC]). 
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Results: Among all 1326 lung cancer patients, 1208 (91.1%) were diagnosed as 
NSCLC and 118 (8.9%) were SCLC. The prevalence o f any co-morbidity' for all 
lung cancer patients was 60.2% and 'at least one co-morbidity' was 51.7%. The most 
frequent co-morbid diseases or conditions in males were hypertension (19.8%), 
COAD (11.9%) and diabetes mellitus (11.2%); while in females they were 
hypertension (29.9%), diabetes mellitus (13.1%) and ischaemic heart disease (13.2%). 
By the end of 2008，1105 (83.3%) patients died and most of them died from lung 
cancer (96.1%, 1062 cases), 163 (12.3%) patients were still alive and 58 (4.4%) 
patients were loss to follow up. The median survival time for the entire cohort was 
10.79 months (range: 0 - 83.4 months). For patients with NSCLC, the median 
survival time was 9.26 months. The median survival duration for SCLC patients with 
limited stage and extensive stage was 13.37 months and 8.59 months, respectively. 
Prognostic factors significantly associated with shorter survival of patients with 
SCLC were Karnofsky Performance Status (KPS) score of less than 70 (HR=2.06; 
95% CI: 1.20-3.54), extensive stage (HR=2.31; 95% CI: 1.44-3.73), and the absence 
of treatment (HR=2.82; 95% CI: 1.53-5.19)，after the major confounding factors were 
adjusted for in the multiple Cox's regression models. 
Prognostic factors significantly associated with shorter survival of patients with 
NSCLC were KPS score of less than 70 (HR=1.53; 95%CI: 1.30-1.81), advanced 
stage, presence of adverse symptoms, (HR=1.44, 95%CI: 1.19-1.74), tumor located 
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either on right side or bilateral (HR=1.18; 95%CI: 1.03-1.34), and the absence of 
treatment (HR=1.65; 95%CI: 1.43-1.90); while patients with BMI>18.5 had 
significantly better prognosis than those with lower BMI. Major confounding factors 
had been addressed in the multiple Cox's regression model. 
Results from in-depth multivariate analysis showed that the presence of any 
co-morbidity significantly increased the mortality of all lung cancers by 17% (95%CI: 
3-33%). However, only a borderline risk was suggested when subgroup analysis was 
performed in SCLC (HR=1.60; 95%CI: 0.94-2.73) and NSCLC (HR=1.14, 95%CI: 
0.99-1.30). A positive but weak gradient with increasing numbers of co-morbidity 
count was observed for both NSCLC (HR=1.0, 1.13，1.21) and SCLC (HR=1.0, 1.60, 
1.67) for co-morbidity count of 0, 1-2, and>2, respectively. 
Multivariate Cox's proportional hazard model showed that major categories of 
co-morbidity significantly associated with inferior survival for all lung cancers were 
diseases of the nervous system and sense organs (HR=1.57, 95%CI: 1.05-2.33), 
diseases of the circulatory system (HR=1.17, 95%CI: 1.01-1.36), diseases of the 
digestive system (HR=1.28, 95%CI: 1.02-1.61) and congenital anomalies (HR=3.55, 
95%CI: 1.64-7.66). After stratification by histological cell type, only congenital 
anomalies (ICD: 740 - 759) had been identified as a significant prognostic factor for 
patients with NSCLC (HR=2.82, 95%CI: 1.12-7.12) and SCLC (HR=6.75，95%CI: 
1.31 -34.75). We further identified that patients with specific disease of 'peripheral 
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vascular disease (ICD: 443)' was significantly associated with an elevated risk of 
death from all lung cancers (HR=2.25，95%CI: 1.24-4.02) and the histological 
subtype ofNSCLC (HR=2.12, 95%CI: 1.19-3.83). None of specific co-morbidity 
disease or condition was associated with an increased risk of death from SCLC. 
Conclusions: The prevalence of co-morbidity is high among Chinese lung cancer 
patients. A significant shorter survival of lung cancer patients was associated with the 
presence of any co-morbidity or any of these pre-existing diseases in the nervous 
system and sense organs, circulatory system, digestive system, and congenital 
anomalies. A positive but weak gradient with increasing numbers of co-morbidity 
count was observed for both NSCLC and SCLC. Although a positive relationship was 
suggested between the risk of lung cancer death and the presence of most major types 
or specific co-morbidity for NSCLC or SCLC, only a few had achieved statistical 
significance, suggesting that statistical power may not be adequate in doing a 
subgroup analysis. Nevertheless, our study conveys a clear message that inclusion of 
co-morbidity information would guide a better medical practice and make a proper 
treatment decision, as well as optimize the clinical management for patients with lung 
cancer. 
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低於 70 分（HR=2.06;95%CI: 1.20 - 3.54) ’ 擴散期（HR=2.31; 95°/oCI: 
1.44 - 3.73)，和缺乏治療（HR=2.82; 95%CI: 153 - 5.19)° 
多因素分析結果亦顯示顯著影響非小細胞型肺癌存活率的因素爲卡氏評分(KPS) 
低於 70 分（HR=1.53; 95%CI: 1.30 - 1.81)‘晚期肺癌(HR=2.31； 95%C1: 
1.44 - 3.73)，症狀的出現旧1^=1.44，95%〇丨：1.19-1.74)，腫瘤處於右邊或雙 




其死亡率會增加17% (95%CI: 3-33%)。但是，對於小細胞型肺癌和非小細胞型 
S市癌病人，合并病對他們存活率的影響只是處於邊緣水平。（小細胞型肺癌病人： 
HR=1.60; 95%CI: 0.94-2.73)(非小細胞型肺癌：HR=1.14, 95%CI: 0.99-1.30)。 
分析同時發現對於非小細胞型肺癌和小細胞型肺癌病人，存在合并病的數目愈多 
風險比率愈高的趨勢（非小細胞型肺癌:HR=1.0，1.13, 1.21)(小細胞型肺癌： 
HR=1.0, 1.60, 1.67)，不過，其計量效應關係不顯著0 
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在多因數Cox比例危險回歸模型分析中’本硏究發現有一些類別的合并病和肺 
癌病人低存活率有明顯的關係°神經系統及感覺器官疾(HR= 1.57 ’ 95%CI ： 
1.05-2.33)、循環系統疾病（HR = 1.17，95%CI ：1.01 -1.36) ’ 消化系統疾病(HR 
= 1 . 2 8 ' 95%CI ： 1.02-1.61)和先天性異常(HR = 3.55 , 95%CI ： 1.64-7.66) 
顯著與肺癌患者低存活率有關係°分層分析發現只有先天性異常( ICD: 740 -
759)顯著與小細胞型肺癌(HR=6.75, 95%CI: 1.31-34.75)和非小細胞型肺癌 
(HR = 2.82，95%CI ： 1.12-7.12)患者低存活率有關係°再者，本硏究發現外周 
血管病（ICD: 443)顯著與肺癌(HR=2.25，95%CI: 1.24-4.02)和其亞型：非小細 
胞型肺癌(HR = 2.12 ' 95%CI ： 1.19-3.83)患者低存活率有關係。至於對於小細 
胞型肺癌病人，沒有一指定的合并病和衹者存活率有關。 
結論：本硏究結果顯示，肺癌患者伴隨合并症是十分常見的。本硏究發現肺癌病 
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Chapter 1: Introduction 
1.1 Epidemiology of lung cancer 
Lung cancer is the most common cancer in the world. In 2002, there were 1.35 
million new cases and 1.18 million deaths from lung cancer worldwide, which 
accounted for 12.4% of all new cancer cases and 17.6% of all cancer deaths 
respectively (Parkin et al. 2005). In Hong Kong, over 15,000 new cancer cases are 
diagnosed every year, and approximately 20% of them are lung cancer; such figure is 
much higher than that of other countries (Parkin et al. 2005). 
Cigarette smoking is the main cause of lung cancer. Around 90% of lung cancer 
among Western population could be attributable to the cigarette smoking (Alberg & 
Samet 2003; Shopland et al. 1995). Besides cigarette smoking, an increased risk of 
lung cancer is also associated with numbers of occupational and environmental 
exposures, such as, arsenic, polycyclic aromatic hydrocarbons, diesel exhaust, 
herbicides and insecticides, silica, asbestos, beryllium, chromium and radiation 
(Bahader & Jazieh 2008; Matteis,et al. 2008; Siemiatycki et al. 2004). Other major 
risk factors of lung cancer are family history of cancer, presence of pre-existing lung 
disease and unhealthy dietary factors (e.g., intake of fried and/or preserved foods) 
(Alberg & Samet 2003). Thus, in order to prevent the lung cancer, it can be done 
partly by means of removing or reducing these risk factors, such as quitting smoking 
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or substituting hazardous occupational exposure in the workplace (Alberg & Samet 
2003). 
In Hong Kong, lung cancer has been the leading cause of cancer death for both 
men and women for decades (Hong Kong Cancer Registry, 2008). According to the 
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statistics from Hong Kong Cancer Registry, 32% and 24% of male and female cancer 
patients died from lung cancer in 2006，and the average 5-year survival rate was only 
15% (Hong Kong (China) Cancer Expert Working Group on Cancer Prevention and 
Screening 2004). The prognosis of lung cancer is generally poor. Even if the 
advancement in treatment technique (e.g. administration of molecular targeted therapy 
for advanced stage patients or real time tumor tracking in radiation therapy) has been 
achieved in recent years (Jeffries et al. 2007; Van der Voort van zyp et al. 2009)，lung 
cancer remains a highly fatal disease. 
Lung cancer patients are usually asymptomatic in the early stage. Most patients 
seeking medical consultation are found at an advanced stage and majority of them 
have metastatic diseases which are usually incurable. Lung cancer can be classified 
into two major types: non small cell lung cancer (NSCLC) and small cell lung cancer 
(SCLC). NSCLC is more common than SCLC, accounting for 80 - 90% of all lung 
cancer cases (Jeffries et al. 2007; Hurria & Kris 2003). Less than 20% of lung cancers 
are diagnosed as SCLC (Jeffries et al. 2007; Hurria & Kris; Gridelli et al. 2007). 
NSCLC and SCLC have been recognized as a separate entity not only because of the 
difference in histological characteristics, but also the difference in the prognosis 
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(Buccheri & Ferrigno 1994). Different prognostic factors may present for patients 
with NSCLC and SCLC (Brundage et al. 2002). 
Previous studies showed that the overall 5-year survival rate for lung cancer 
patients was approximately 15% (ranged l%-60%), and the variation of survival rate 
was associated with the histology and stage of lung cancer at the time of diagnosis 
(Brundage et al. 2002). Surgery is the treatment of choice for patients with early-stage 
NSCLC. However, previous studies showed that 75 - 85% of NSCLC patients were 
not eligible for curative treatment because of the extent of local tumor, metastatic 
diseases or presence of co-morbidity (Hong Kong (China) Cancer Expert Working 
Group on Cancer Prevention and Screening 2004，Stevens et al. 2007, Toy et al. 
2003). SCLC has long been recognized as a fast-growing type of cancer with a rapid 
spread (Schiller 2001), and distant metastasis is common at its initial presentation. 
Surgical resection is only considered in the rare situation when patients have limited 
SCLC. Chemotherapy is usually the primary treatment for patients with SCLC and 
supplemented by radiation therapy. With the combination of chemotherapy and 
radiotherapy, the median survival time for patients with limited stage of SCLC is 
approximately 12-16 months and for patients with extensive stage the average 
survival period is only 6 - 1 1 months (Rossi et al. 2005). 
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1.2 Overview of significant prognostic factors for patients with NSCLC 
Prognostic factors play an important role in explaining the survival outcomes of 
patients with NSCLC. Thus, identifying the prognostic factors would benefit to 
understanding disease nature, making treatment decision, and advising on patient 
management (Brundage et al. 2002). 
Brundage and his colleagues (2002) conducted a comprehensive literature review 
on the prognostic factors of lung cancer, and summarized that over 150 prognostic 
factors were potentially related to survival of NSCLC. Among those identified 
prognostic factors, some were tumor related factors and some were patient related 
factors. For patients with resectable NSCLC, the Tumor, Node and Metastasis (TNM) 
staging, as well as the performance status were the major factors potentially 
influencing the prognosis of lung cancer and individual patient management (Strauss 
1997). In addition, weight loss of about 10% within 6 months before diagnosis is 
another important prognostic factor for the poor survival of patients with advanced 
stage of NSCLC (Buccheri & Ferrigno 1994; Paesmans et al. 1995). 
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1.2.1 Tumor related factors 
Tumor related factors include TNM staging and histological cell type. 
TNM staging system was developed by American Joint Committee of Cancer 
(AJCC) and The International Union Against Cancer (UICC) in 1985 and it was 
further revised in 1997 to allow a greater specificity in identifying patient groups with 
a similar prognosis and treatment option. The system provides information on the 
tumor load and spread, which is used to determine the extent of diseases. Based on the 
TNM staging system, non small cell lung cancer can be subdivided into four stages, 
ranging from stage I，II，III，to IV. In general, more advanced stages correlate with 
worse survival outcomes. Evidence has consistently demonstrated that the stage, 
regardless of clinical and pathological staging, is an independent prognostic factor for 
survival of early staged patients. However, conflicting results are shown among 
patients with advanced stage of III and the above. 
It is controversial on whether the current TNM staging system alone can 
sufficiently predict the prognosis of NSCLC for guiding clinical management in 
routine practice. TNM staging system has been recognized as a great tool to predict 
the prognosis of operable lung cancer patients because TNM staging system provides 
clear definition on the anatomical extent of tumor helping in determination on the 
status of operability，while such staging system may not be suitable for non operable 
lung cancer patients (Solan & Werner-Wasik 2003; Chen et al. 2002). 
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There are 4 major histological cell type of lung cancer according to the World 
Health Organization histological classification，including squamous cell carcinoma, 
adenocarcinoma, large cell carcinoma and small cell lung carcinoma (Brambilla et al. 
2001). The former three subtypes are collectively grouped as NSCLC. It is well 
established that patients diagnosed as NSCLC have survival advantage over those 
diagnosed as SCLC (Goldman 1965). The prognostic significance on survival for the 
3 histological subtypes of NSCLC was different from each other. Goldman (1965) 
reported that the prognosis was better for patients with squamous cell type of lung 
cancer than those with adenocarcinoma or large cell carcinoma regardless of the 
operable status (Goldman 1965). And the cell type of lung cancer was reported to 
closely link to the prognostic outcomes in the first 6 - 1 2 months of survival, while 
the effect disappeared afterward (Goldman 1965). 
Nevertheless, a more recent historical cohort study conducted by the Japanese 
Joint Committee of Lung Cancer Registry did not observe any significant difference 
in survival time among 6644 resected NSCLC patients of various cell types (i.e., 
adenocarcinoma, squamous cell carcinoma and large cell carcinoma) (Goya et al. 
2005). Variations on the length of survival in different studies may be related to 
different criteria to categorize lung cancer patients: bronchioloalveolar carcinoma was 
included as the histologic category of adenocarcinoma in Goya's study (2005), while 
it was excluded in Goldman's study (1965). Bronchioloalveolar carcinoma was 
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generally considered as non-invasive and had better prognosis (Breathnach et al. 
2001). 
1.2.2 Patient related factors 
Patient related factors affect the survival ofNSCLC including the performance 
status, symptom presentation, and co-morbidity. 
Besides TNM staging and histological cell types, general health status of the 
affected person (also named 'patient related factors') is an important factor to 
determine the survival of lung cancer. Important patient related factors potentially 
affecting the prognosis of lung cancer are socio-demograpliics (e.g. gender, smoking 
and alcohol drinking status), performance status, symptoms, and co-morbidities 
(Glare 2005, Ninane et al. 2003). Presences of poor performance status, symptoms 
(especially the weight loss) and co-morbidities have been found to be significantly 
associated with negative impact on survival in patients with non small cell lung 
cancer. , 
Performance status is used to assess the functional status of patients (Mor et al. 
2002). It measures the extent of a patient's functional impairment on the basis of 
his/her ability to perform normal activities of daily living, work capacity, and degree 
of self-reliance (Schubert, Gross & Hurria 2008). The most commonly used scales are 
Karnofsky Performance Status (KPS) and Eastern Cooperative Oncology Group 
(ECOG PS). The performance status (KPS and ECOG PS) has been established as one 
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of the most significant prognostic factors for patients with lung cancer (Buccheri & 
Ferrigno 1994). In general, patients with good performance status have a better 
prognosis than those with poor performance status (Buccheri & Ferrigno 1994, 
Stanley 1980). 
The presence of symptoms may partly reflect the more advanced disease 
progress of lung cancer. Most patients have already presented certain symptoms at the 
first consultation for lung cancer, suggesting lung cancer is a kind of disease that is 
hard to be identified at the early stage. Symptoms, especially body weight loss of 
greater than 10% within 6 months prior to the diagnosis is the most important 
prognostic factor negatively associated with the survival of patients with lung cancer 
(Stanley 1980, Dewys et al. 1980, Ross et al. 2004). Previous studies showed that 
patients without any symptoms had survival advantage over those with the symptoms 
(Oh 2004). 
1.3 Overview of significant prognostic factors for SCLC patients 
Compared with NSCLC patients, the prognosis of patients with SCLC is less 
satisfactory despite great improvements in diagnosis and treatment have been 
achieved in the past several years. The overall 5-year survival for patients with SCLC 
is only about 5%. Untreated patients with limited stage and extensive stage of SCLC 
have median survival of 3 and 1.5 months respectively. With the combination of 
chemotherapy and chest radiotherapy, the median survival is only extended to 10 - 16 
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months for patients with limited stage SCLC and to 6 - 11 months for patients with 
extensive stage SCLC (Rossi et al. 2005). 
SCLC is an aggressive and rapidly growing tumor. Besides its aggressive nature 
and frequently widespread metastasis, patients usually have advanced disease at the 
time of diagnosis (Beadsmoore & Screaton 2003). More advanced disease extent, 
poor performance status, and elevated level of lactate dehydrogenase (LDH) have 
been consistently identified as important risk factors for the poor prognosis of SCLC 
(Mohan et al. 2006, Paesmans et al. 2000, Yip & Harper 2000). 
Similar to NSCLC, stage is considered as an important prognostic factor to 
predict survival and guide treatment for SCLC patients. Veterans Administration 
Lung Cancer Study Group classifies SCLC patients into 2 groups: limited and 
extensive disease (Socinski & Bogart 2007). Limited disease was confined to the 
hemithorax, the mediastinum, or the supraclavicular nodes, which can be 
encompassed within a tolerable radiotherapy port. Extensive disease was defined as 
one has spread beyond the supraclavicular area and is too widespread to be included 
(Mountain 1978). Patients with limited disease generally have better outcome than 
those with extensive stage. For patients with extensive stage, increased number of 
metastatic sites was significantly related to worsening prognosis (Giannone et al. 1987; 
Li et al. 2010). 
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Performance status reflecting the prognostic significance of pretreatment status is 
also associated with the prognosis of SCLC. Performance status has been documented 
not only as a useful prognostic factor to predict survival of SCLC patients, but also as 
a good marker to assess the quality of life and response to therapy (El-Helw et al. 
2008). 
Besides the stage and performance status, pretreatment clinical factors and 
numbers of biochemical factors were found to be the independent prognostic factors 
to predict survival of SCLC (Li et al. 2010). 
LDH is an enzyme which is commonly found in the organisms of human being. 
It plays an important role in cellular respiration and is a non-specific indicator of 
many diseases (Jakubik et al. 2003). Its isoenzyme LDH3 is also a strong prognostic 
determinant for the progress of patients with SCLC (Jakubik et al. 2003). Evidence 
has shown that elevated levels of LDH and LDH3 were associated with significantly 
poorer survival for patients with SCLC, especially for those with limited disease. 
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Chapter 2: Literature Review 
2.1 Prevalence of co-morbidity among lung cancer patients 
Co-morbidity (literally "additional morbidity") is defined as the presence of 
co-existing or additional diseases with reference to an index diagnosis. Co-morbidity, 
in general, can include the co-occurrence of mental (depression) or physical disorders 
(Hall 2006). Nevertheless, co-morbidities should not be related to the index condition 
or side effects or complications of treatment (Piccirillo & Costas 2004, Aksoy et al. 
2006，Fried et al. 2004). 
Chronic diseases, such as, cardiovascular diseases, diabetes mellitus, and/or 
respiratory diseases, are prevalent among elderly population (Deppermann 2001, 
Gridelli et al. 2007). It was estimated that 86% of the elderly population had at least 
one chronic illness (Lindsey et al. 1994). It is very common that cancer patients, 
especially for the elderly, co-presented with some chronic illness at the time of 
diagnosis that might shorten the survival of lung cancer (Battafarano et al. 2002). The 
presence of co-morbidity is thus a significant concern in elderly patients with cancer. 
A study of 15626 population-based incident cases of cancer showed that 
co-morbidity was present in 68.7% of cancer patients and it was found that 32.6% of 
them had 2 or more co-morbid conditions (Ogle et al. 2000). Lung cancer patients had 
higher prevalence of cardiovascular, respiratory and cerebrovascular disease. In the 
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study of Ogle (2000)，co-morbidity was obtained by interviewing patients to ask if 
they had ever experienced any chronic condition. Only six chronic diseases were 
included in the co-morbidity list: cardiovascular diseases, diabetes, cerebrovascular 
diseases, hypertension, respiratory diseases and arthritis (Ogle et al. 2000). 
A large population based study including 43111 newly diagnosed patients with 
various types of cancer was conducted between 1995 and 2002 in the Southern 
Netherland (Janssen-Heijnen et al ‘ 2004). About 60% of these cancer patients were 
older than 65 years and suffered from at least one chronic condition. The study 
revealed that the prevalence, severity and numbers of co-morbid conditions of elderly 
patients increased with advancing age. Compared with other cancer types, the 
prevalence of co-morbidities was the highest in lung cancer patients, regardless of sex 
and age (Janssen-Heijnen et al. 2004). Co-morbidities was present in about 50% of 
cancer patients aged 50 years old, while it rose to about 70% for the patients above 65 
years old (Gridelli et al. 2007, Janssen-Heijnen et al. 2004). 
Lung cancer is strongly associated with advanced age and smoking, and both age 
and smoking are strongly associated with numerous chronic diseases, such as 
cardiovascular diseases and chronic obstructive pulmonary diseases (Hsie et al. 2009, 
Tammemagi et al. 2004b, Wang et al. 2007). Therefore, the presence of co-morbidity 
might be resulted from aging and cigarette smoking. 
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A retrospective cohort study of 1155 lung cancer patients from US found that 
nearly 90% of patients had at least one co-morbid disease and over half of the 
population had 3 or more co-morbidities at the time of diagnosis of cancer 
(Tammemagi et al. 2003). Previous studies consistently showed that advanced age 
was significantly associated with increasing numbers of co-morbidity (i.e., 
co-morbidity counts) (Janssen-Heijnen et al. 2005; Tammemagi et al. 2003). 
Tammemagi and his colleagues (2003) suggested that higher consumption of cigarette 
smoking (pack-years), female gender, former smoking status, lower socioeconomic 
status and heavy alcohol use were the independent predictors for the presence of high 
co-morbidity counts. In addition, the elderly who were the long-term chronic smokers 
were particularly predisposed to the occurrence of chronic obstructive pulmonary 
diseases (COAD) and cardiovascular diseases (Tammemagi et al. 2003). 
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2.2 Impact of co-morbidity on non small cell lung cancer patients 
Co-morbidity is known as an independent prognostic factor for patients with a 
variety of cancers, e.g. breast, colon, prostate and head and neck cancers (Tammemagi 
et al. 2004a; Extermann 2004; Tiemey et al. 2002). The presence of co-morbidity and 
the complexity of coexistent diseases not only influence the choice of treatment and 
patient management (Hall 2006), but also affect patient's response to therapy and the 
survival rate (Satariano & Silliman 2003). Both the number and type of co-morbid 
condition might influence the overall survival rates of cancer patients after the 
adjustment of age, sex, stage of diseases and other important prognostic factors (Yates 
2001). The presence of chronic obstructive pulmonary disease had shown a major 
impact on the prognosis of early stage lung cancer patients who underwent surgery, 
while renal disease had a great effect in those receiving chemotherapy (Satariano & 
Silliman 2003). 
The importance of co-morbidity in patients with lung cancer was initially 
addressed by Feinstein and his colleagues (Battafarano et al. 2002). However, its 
prognostic significance remains controversial and the prognostic impact differs across 
various stages of lung cancer patients. Nevertheless, the presence of co-morbidity was 
considered to be an important prognostic factor adversely influencing the survival of 
lung cancer patients after surgical resection (Limmer et al. 2009). It was estimated 
that about 19 -30% of early staged NSCLC patients who underwent surgery died 
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from other chronic diseases, such as COAD and cardiovascular diseases (Ambrogi et 
al. 2003). 
Battafarano et al. (2002) retrospectively reviewed 480 stage I lung cancer 
patients who underwent surgical resection between 1994 to 1999. The co-morbid 
information was rated by using Kaplan-Feinstein index (KFI) with slight 
modifications by including diabetes mellitus and other co-morbid conditions which 
were not present in the original KFI. Among these 480 patients, 451 (94%) had 
determined the severity scores of co-morbidity at the time of diagnosis. During the 
follow-up period after diagnosis, 128 (28%) patients died, and the common cause of 
death was cardiovascular disease, followed by secondary malignancy. It was found 
that patients with increasing severity of co-morbidity were more likely to die from 
other causes. With regards to the overall survival of patients with lung cancer, this 
study found that concurrent co-morbidity was independently associated with inferior 
overall survival, after adjustment of T stage, age, gender and the histological type. 
Compared with patients without any co-morbidity, patients with moderate and severe 
co-morbidity had significantly increased the risk of death after a mean duration of 
follow-up of 35.7 months (Battafarano et al., 2002). 
Moro-Sibilot et al. (2005) retrospectively reviewed 588 stage I patients who 
underwent surgical resection for primary non small cell lung cancer patients between 
1979 and 2003. The co-morbid condition was recorded and assessed by using 
Charlson Co-morbidity Index (CCI) score. It was found that the most prevalent 
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co-morbidity in the study was chronic pulmonary disease. With a median duration of 
follow up of 104 months, results from Mor-Sibilot's study showed that CCI score of 
greater than 2 had worse prognosis for lung cancer after adjustment for age, 
pathological T status and individual co-morbid conditions (HR: 1.81; 95% C.I.: 1.25 -
2.63). With regards to individual co-morbid conditions, although chronic pulmonary 
disease was the most prevalent disease in this study, it did not demonstrate any 
prognostic significance in both univariate and multivariate analysis. On the other hand, 
presence of moderate to severe liver disease, previous history of cancer (any tumour 
within 5 years of diagnosis) and cerebrovascular disease were significant prognostic 
factors of survival. 
Birim, Kappetein & Bogers (2005) retrospectively reviewed 433 patients who 
underwent surgical resection for all stage of primary non small cell lung cancer during 
1989 to 2001. The co-morbid information of each patient was assessed preoperatively 
by using CCI. The three most common co-morbidities were chronic pulmonary 
disease, coronary artery disease and peripheral vascular disease. The multivariate 
Cox's proportional hazard analysis showed that CCI score was an independent 
prognostic factor, which negatively affected the long-term survival of patients, after 
adjustment for age, gender, type of resection, stage and individual co-morbid 
conditions. However, findings from Birim, Kappetein & Bogers were inconsistent 
with those from Moro-Sibilot's study (2005), because none of individual specific 
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co-morbid conditions were identified as the significant prognostic factors for the 
survival of patients with NSCLC in the later study. 
In a study of 78 patients with pN2 non small cell lung cancer who received 
complete resection of either lobectomy or pneumonectomy including regional 
dissection of lymph nodes, 38.5% of patients were found to have various conditions of 
co-morbidity, with the most prevalent type of diabetes mellitus; however, the method 
used to collect co-morbid information was not clearly stated in the study (Tomita et al. 
2006). Despite the authors found that the presence of co-morbidities was significantly 
associated with poorer survival in univariate analysis, its independent effect on the 
prognosis of lung cancer disappeared after nodal status and serum carcinoembryonic 
antigen level were further adjusted in the multivariate data analyses (Tomita et al. 
2006). 
Co-morbidity index is commonly used to assess the severity of co-morbidity. 
The principle of index is to summarize all the co-existent diseases and the severity of 
those illnesses to a single score. CCI was originally developed by Charlson and her 
colleagues in 1987 (Charlson et al. 1987), which has been the most commonly used 
tool to assess the prevalence of co-morbidity and the impact on lung cancer. In 
Charlson's study (1987), a cohort of 559 patients with a variety of different medical 
conditions were recruited from a medical unit and followed up for 1 year to observe 
the overall mortality; 19 conditions were found to be significantly influencing the 
survival of patients but at a different magnitude. They therefore employed a specific 
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weight to each co-morbid condition according to the relative risk of the mortality, and 
then summed up the weighted score of each co-morbid condition to develop an overall 
score of CCI. CCI has been recognized as an inexpensive, simple and readily 
available tool to record co-morbidity data. Its advantage is to provide a whole picture 
of the patient's health status by using an overall index and allow for a reliable 
comparison with the health statuses of other patients and with the findings from other 
studies (Hall 2006; Semrau et al. 2008). 
Besides Charlson co-morbidity index, Kaplan-Fleinstein Index (KFI) was also 
used to assess the impact of co-morbidity on survival of surgical non small cell lung 
cancer patients, but its prognostic significance is controversial (Wang et al. 2007). 
The KFI was originally developed by Kaplan and Feinstein in 1974 but it was slightly 
modified in recent years by further including diabetes mellitus and other co-morbidity 
which were not included in the original KFI (Battafarano et al. 2002; Satariano & 
Silliman 2003). 
Battafarano (2002) retrospectively reviewed 451 patients who underwent 
surgical resection for pathologic stage I non-small cell lung cancer between January 1， 
1994, and December 31, 1999, with a mean duration of follow-up of 35.7 months. The 
modified KFI, which included diabetes mellitus, was used to evaluate the co-morbid 
condition of patients. It was found that the modified KFI had a significant impact on 
the survival of patients after surgical resection, after controlling for age, gender, T 
status, and histological type of tumor. Patients with moderate severity of co-morbidity 
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(relative risk: 2.28; 95% C.I.: 1.43-3.65) and severe severity of co-morbidity (relative 
risk 1.94; 95% C.I.: 1.023-3.70) significantly increased the risk of death. 
Wang et al. (2007) retrospectively reviewed 426 stage I patients who had 
underwent complete surgical resection for primary lung cancer. Two co-morbidity 
indexes, CCI and Kaplan Feinstein Index (KFI), were used to record the co-morbid 
conditions. CCI was considered to be a better indicator of co-morbidity than KFI in 
predicting the prognosis of lung cancer patients. CCI score of 2 or higher was shown 
to be an independent prognostic factor for lung cancer survival after taking age, sex, 
smoking status, stage, histology and treatment in consideration (Hazard ratio [HR]: 
1.74，95% C.I.: 1.25-2.42). 
Although previous studies had shown CCI as a good indicator in evaluating the 
impact of co-morbidity on the survival of surgical lung cancer patients, results tended 
to be inconsistent for patients with different stage of disease. Birim and his colleagues 
(2003) retrospectively reviewed 126 patients at age of 70 years or older who 
underwent pulmonary resection for non small cell lung cancer, and found that CCI 
score of 3 to 4 was a significant factor for the major complication within 30 days of 
surgery. Nevertheless, the effect of CCI on the long-term survival (5-year) of lung 
cancer was not statistically significant, which might be explained by relatively small 
sample size of the study (Birim et al. 2003). Previous reports concerning the effect of 
. co-morbidity on the survival of lung cancer patients with advanced stage have been 
subject to controversial (Tammemagi et al. 2003; Janssen-Heijnen et al. 2004). 
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Li et. al. (2008) retrospectively reviewed 177 elderly patients with either stage III 
or IV who had good performance status (ECOG PS ^ 2 ) and had received systemic 
chemotherapy. CCI was also used to measure the co-morbidity of the patients. It was 
found that patients with severe co-morbidity (i.e. CCI ^ 3) was a significant 
independent prognostic factor for the poor survival (HR: 2.09; 95%CI: 1.06-4.15) 
after adjustment for gender, age, histological cell type, stage and treatment status. 
Blanco et al. (2008) retrospectively reviewed 294 patients with either stage IIIB 
or stage IV non small cell lung cancer patients between year 1997 and 2006. They 
defined the co-morbidity as any disease present 12 months before the date of cancer 
diagnosis. All the co-morbid information was recorded by CCI scale. Multivariate 
Cox's proportional hazard analysis showed that numbers of co-morbidities of 2 or 
more was significantly associated with poorer survival, after adjustment of age，sex, 
treatment status, presence of weight loss and specific types of co-morbidities. With 
respect to individual co-morbid diseases, the combination of CO AD and 
cardiovascular disease was shown to negatively influence the survival of patients in 
univariate analysis, but the prognostic effect was no longer statistical significance 
after the major confounding factors were adjusted in multivariate analysis. Small 
number of patients included in the subgroup analysis might offer an explanation on 
the insignificant results. 
Li et al. (2009) retrospectively reviewed 109 NSCLC patients who were 
unresectable and locally advanced and metastatic cases receiving chemotherapy 
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between 1999 and 2006 in China. All eligible patients recruited in this study were 70 
years old or older. Consistent with the study conducted by Blanco et al. (2008)， 
patients presenting more than 2 co-morbidities were significantly associated with 
inferior survival after adjustment for performance status, treatment cycle and 
prescription of second line therapy. 
With regards to the impact of individual co-morbidity on the survival of lung 
cancer patients, Vasic (2007) conducted a prospective study among 87 patients with 
either stage III or stage IV non small cell lung carcinoma during May 2005 to 
December 2006, and found that the length of survival depended on performance status 
(coded by Karnofsy Performance Status), stage of disease, and specific co-morbidities 
(i.e., chronic myocardiopathy, type II diabetes mellitus, myocardial infarction). 
However, the results were considered instable given inadequate number of cases 
included in the multivariate analysis. 
In contrast to studies mentioned above, Maione et al (2005) recruited 566 stage 
IIIB or IV NSCLC patients aged 70 years or above and had baseline ECOG PS level 
as well as treated by chemotherapy to a randomized controlled trial. The 
co-morbid situations were summarized by using CCI scale. It was found that CCI 
score had no prognostic value and was not associated with overall survival in two 
treatment arms (the combination of vinorelbine and gemcitabine vs. vinorelbine alone 
or gemcitabine along (Maione et al. 2005). 
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Firat, Byhardt & Gore (2002) conducted a study on 112 stage III NSCLC 
patients who were treated with radiotherapy alone according to various fractionation 
scheme. The Cumulative Illness Rating Scale for Geriatrics (CIRS-G) and CCI score 
were used to record the co-morbid conditions. It was found that neither CCI score nor 
CIRS-G score were significantly associated with survival. 
Janssen-Heijnen et al. (2004) conducted a retrospective population-based cohort 
study, involving 4072 elderly NSCLC patients in the Netherlands by using CCI to 
record the co-morbid conditions. It was found that CCI score, the co-morbidity 
counts, and individual co-morbidities were not significantly associated with overall 
survival, which was independent of stage in both the univariate and multivariate 
analysis. 
In summary, unlike the studies conducted for early staged NSCLC patients, the 
prognostic value of co-morbidity index, e.g. CCI, has been subject to controversy in 
NSCLC patients with advanced stage. Most previous studies had concentrated on 
evaluating the impact of co-morbidity index on the survival, but paid little attention 
on evaluating the impact of specific co-morbid condition on the survival, especially 
among studies involving lung cancer patients with advanced stage. 
2.3 Impact of co-morbidity on small cell lung cancer patients 
Co-morbidity is also prevalent among SCLC patients. A population based study 
showed that more than 60% of patients had at least one co-morbid condition at the 
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diagnosis of SCLC (Janssen-Heijnen et al. 2007). The high prevalence of 
co-morbidity was due to advanced stage and cigarette smoking. Similar to NSCLC, 
the presence of co-morbidity was also thought to be a negative prognostic factor for 
the prognosis of patients with SCLC, but its relationship with SCLC survival has not 
yet been clearly established. 
Several hospital based studies regarding the association between the presence of 
co-morbidity and SCLC had been studied (Shepherd et al. 1994; Gonlugur & 
Gonlugur 2006). Gonlugur & Gonlugur (2006) reviewed medical records of 90 
histologically confirmed SCLC patients who were between 39 and 80 years old 
consecutively, and divided the co-morbidity into two groups: the presence of COAD 
and other co-morbidities. The authors found that 34% of patients had co-morbidities 
other than COAD. Univariate analysis showed that patients without co-morbidity had 
survived significantly longer than those with any co-morbidities other than COAD 
(median survival: 5 months vs 8 months, p=0.01). The independent prognostic effect 
still remained after taking stage, performance status into consideration in multivariate 
analysis (Gonlugur & Gonlugur 2006). However, the presence of COAD had no 
significant effect on survival in both univariate and multivariate analysis. 
Medical records of 123 SCLC patients who were 70 years or older treated 
between 1976 and 1998 in Toronto Hospital, Canada were retrospectively reviewed 
by Shepherd et al (1994). Among these patients, more that 10% of patients were older 
than 80 years old. All the co-morbid diseases which were present before the diagnosis 
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of SCLC were included. It was found that approximately 80% of patients had 
co-morbid diseases and the most prevalent type of co-morbid diseases was 
symptomatic chronic obstructive pulmonary disease. It was interestingly found that 
there was no difference between age groups (70-74, 75-79, 80 or greater) with respect 
to presence of co-morbidity. In this study, the presence of co-morbid disease was not 
a significantly prognostic factor for overall survival after adjustment of stage, 
treatment, age and performance status (Shepherd et al. 1994). This study had 
advantages that the follow up was complete and the duration was adequate. However, 
it mainly focused on the elderly patients who were greater than 70 years old, and the 
findings can hardly be generalized to all SCLC patients. 
Medical records of 174 limited stage SCLC patients who were between 35 and 
86 years old were retrospectively reviewed by Ludbrook and his colleagues (2003). 
Data on patient characteristics, treatment and clinical outcomes were collected. In that 
study, co-morbidity was evaluated by using the number of co-morbidities, type of 
co-morbidity and CCI. It was found that 77% of patients had at least one co-morbid 
disease at the time of diagnosis of SCLC and 16% of them even had 3 or more 
co-morbid diseases. The most prevalent type of diseases was chronic obstructive 
pulmonary disease (COAD), followed by cardiovascular disease, diabetes mellitus 
(DM), dementia or cerebrovascular disease. It was found that the numbers of 
co-morbidities of 3 or more was significantly associated with thoracic relapse (HR: 
3.13; 95% C.I.: 1.15 - 8.53). Similar with study conducted by Shepherd and his 
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colleagues (1994), there was no association between co-morbidity and overall survival 
after adjustment of treatment, age, performance status, LDH and presence of weight 
loss, regardless of the type of co-morbidity index (i.e., CCI or the numbers of 
co-morbidity) (Ludbrook et al. 2003). One of the advantages of this study was that the 
number of important prognostic factors, e.g. LDH level and symptoms were collected 
and considered. Although the study population might be able to represent all patients 
with limited stage of SCLC, selection bias may still be introduced because 2 case 
records could not be located appropriately. 
Only a few population-based studies regarding the association between the 
presence of co-morbidity and SCLC had been studied (Janssen-Heijnen et al. 2007). 
Janssen-Heijnen et al. (2007) conducted a large population based study, involving 
1664 newly diagnosed SCLC patients diagnosed between 1995 and 2002 in the 
southern part of the Netherlands, In this study, co-morbidity was evaluated by using a 
slightly modified version of the CCI. Compared with hospital-based study, the 
prevalence of co-morbidity was slightly lower. It was found that 61% of patients had 
at least one co-morbid disease at the time of diagnosis. The most prevalent co-morbid 
disease among male was COAD, while female patients were more likely to have 
COAD and cardiovascular diseases. With respect to overall survival, it was found that 
patients with DM and COAD seemed to have worse prognosis in univariate analysis. 
However, after adjustment for age, gender and treatment, none of the specific 
co-morbid condition was significantly associated with overall survival. 
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Selection bias was unlikely to occur for this study as all newly diagnosed cancer 
patients in the southern part of the Netherlands were registered in Cancer Registry. 
However, information bias could not be excluded as 7% of patients had no 
information on co-morbidity. Furthermore, some of important prognostic factors，e.g. 
performance status, LDH level and smoking data were not collected or considered in 
Cox's regression analysis. 
In summary, except for one hospital based study, other studies, including 
population based study included in this literature review showed that there was no 
significant association between the presence of co-morbidity and overall survival of 
SCLC patients. It was hypothesized that chronic co-morbid conditions tends to take 
time to show their effects. As consequences, co-morbidity may not have sufficient 
latent time to exert a significant impact on the prognostication for such an aggressive 
and fast progressing SCLC (Piccirillo & Costas 2004, Janssen-Heijnen et al. 2007， 
Read et al. 2004). 
2.4 Summary of evidence from literature review 
All studies included in the literature review were retrospective studies by 
reviewing medical records. Retrospectively reviewing medical record is an important 
methodology in survival studies. It has several advantages, including a relatively 
inexpensive ability to gather large amount of data; easier access to conditions where 
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there is a disease with long latent period. Yet, it also has potential disadvantages, 
including incomplete documentation, variation in the quality of information recorded 
by different medical professionals (Gearing et al. 2006). 
In this literature review, it was found that the prevalence of co-morbidity among 
lung cancer patients was high; however, the impact of co-morbidities on the survival 
of lung cancer patients has been subject to controversy, especially among advanced 
stage NSCLC and SCLC patients. Also, there are few studies having been conducted 
in Chinese population. Up to our knowledge, there is no relevant study conducted in 
Hong Kong, thus it is worthwhile to investigate the impact of co-morbidities on the 
survival of lung cancer patients in Hong Kong. Integrating knowledge on the impact 
of co-morbidities, cancer stage and other prognostic factors can help guide therapeutic 
approach by providing optimal treatments to patient care and making a more accurate 
prediction of prognosis. 
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Chapter 3: Aim and Objectives 
3.1 General aim 
The general aim of this historical cohort study is to investigate the relationship 
between co-morbidities and survival experiences for patients with primary lung 
cancer in Hong Kong Chinese. 
3.2 Specific objectives 
The objectives of this study are described as follows: 
1. To describe the prevalence of co-morbidity among lung cancer patients in Hong 
Kong Chinese. 
2. To examine the relationship between co-morbidity and survival of lung cancer in 
the subgroup of patients with non small cell carcinoma and small cell carcinoma. 
3.3 Main hypothesis 
Lung cancer patients with the presence of co-morbidities have poorer survival 
than those without any type of co-morbidities. 
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Chapter 4: Methodology 
4.1 Research design 
This was a historical cohort study to examine the relationship between 
co-morbidities and survival among patients with primary lung cancer in Hong Kong 
Chinese. 
4.2 Study population 
1791 patients who had been previously enrolled in 2 case-control studies, 
regarding the association between cooking fume and the risk of female lung cancer, as 
well as the association between occupational exposure and the risk of male lung 
cancer (Tse et al. 2009，Yu et al. 2006) were included in this study. All cases were 
recruited in the largest oncology center in Hong Kong. 
All cases were newly diagnosed primary lung cancer and the duration between 
the date of diagnosis and the date of first seen in clinical oncology department was not 
more than 3 months. Cases were eligible if they were Chinese, aged 35 - 79 at the 
date of diagnosis, and histologically confirmed primary carcinoma of lung (IDC-9 
code 162) by pathological, histological, cytological, or immune-histochemistry 
examination. Those patients with cancer history were excluded from this study. 
Patients with insufficient evidence of lung cancer, e.g. unknown primary, 
unavailability of histological or pathological confirmation were not eligible in this 
study. In addition, patients aged above 79 were also excluded to avoid the increasing 
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diagnostic ambiguity with advancing age. Based on the above inclusion and exclusion 
criteria, a total of 1326 lung cancers were eligible and retained in the final data 
analyses. 
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4.3 Sample size estimation 
The main objective of this study was to examine the impact of co-morbidity on 
survival of lung cancer. After conducting a comprehensive literature review, we found 
that the minimum hazard ratio for the effect of co-morbidity on lung cancer survival is 
1.2 (Asmis et al. 2008), which ensures the most conservation sample size estimation 
of this study. We formulated the hypotheses as follows: 
Null hypothesis: the proportion of those lung cancer patients who eventually died 
at the end of the study is the same for both the group with co-morbidities and the 
group without co-morbidities (Ho： HR=1). 
Alternate hypothesis: the proportion of those lung cancer patients who eventually 
died at the end of the study is different between the group with co-morbidities and the 
group without co-morbidities (Ho： HR^ 1). 
We assumed that the mortality rate for all causes of death and lung cancer among 
lung cancer patients occurs evenly throughout the entire follow-up period. Based on 
the most conservative hazard ratio (HR) of 1.2, and giving an alpha error at the 5% 
significance level (two-sided) and power of 80%, as well as assuming 50% of patients 
with co-morbidities having died within one year after diagnosis, we estimated that a 
total of 390 subjects with co-morbidities and 390 subjects without co-morbidities are 
required for achieving the research objective of this study. Our cohort study with 1326 
eligible lung cancer cases would be sufficient for lung cancer survival analysis with a 
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power of almost 100%. We used the following formula recommended by Lwanga 
S.K. & Lemeshow S to estimate the sample size for cohort studies (Lwanga & 
Lemeshow 1991). 
— + Zi—" V ^ l + R-p,(l + R' )1}2 
n: minimum required sample size 
： Z value (two tailed) corresponding to the alpha error 
Z,_p :Z value corresponding to the beta error 
R: relative risk of co-morbidities 
/3j: proportion of death from all causes of diseases among the lung cancer patients 
with absence of co-morbidities 
P - 2 
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4.4 Data collection 
Each patient's data were retrospectively reviewed and extracted from hardcopies 
of medical records and/or clinical management system (CMS). CMS is a 
computerized patient record system, which has been developed by the Hospital 
Authority since 1994. The comprehensive records of patients are available on-line 
with data integrated from all sites, with maximum coverage of 40 hospitals and 120 
clinics in the territory (Cheung, Fung & Kong 2004). 
Information included in the data extraction form were demographics, 
co-morbidities, adverse symptoms, disease characteristics, the baseline laboratory 
findings, and treatment data. 
4.4.1 Demographic information 
Demographic information included date of birth, data of first seen in clinical 
oncology department, the patient's age, gender, smoking habits, alcohol drinking 
habits, history of drug abuse, body height and body weight at the date of lung cancer 
diagnosis，and performance status. Body height (meter) and body weight (kilogram) 
were used to calculate the body mass index (BMI) which was expressed as 
BMI = Weight(kg), Health Organization, 2006). Body mass index was 
[height(m)]" 
defined at normal range if it is from 18.5 to 24.9 kg/m" according to the WHO criteria 
(World Health Organization, 2010). 
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Information on smoking history was collected including smoking status, years of 
smoking, numbers of cigarettes smoked per day, and years of smoking cessation. 
Smoking status was classified as current smoker, former smoker and never smoker. 
Smoking pack-years were the product of numbers of packages of cigarettes smoked 
per day and numbers of years smoked. The smoking history data was collected from 
two population-based case-referent studies conducted in Hong Kong during 2004 -
2006 (Tse et al. 2009; Yu et al. 2006). Current smokers were defined as persons who 
had smoked more than 100 cigarettes in their lifetime and were still smoking at the 
time of the survey. A non-smoker was defined as one who had never smoked as many 
as 20 packs of cigarettes or 12 ounces of tobacco in his/ her lifetime or 1 cigarette a 
day or 1 cigar a week for 1 year (Tse et al. 2009). 
Information on alcohol drinking history was collected from patient records, and 
it was classified as current drinker, former drinker and never drinker. Current drinker 
was defined as one who had at least one drink of beer, wine, or liquor in the previous 
12 months. "One drink" is defined as 12 ounces of beer, 4 to 5 ounces of wine, or 1.5 
ounces of spirits. Those social or binge drinker, which was defined as drinking 
alcohol at irregular interval, was also classified as current drinker. Former drinker was 
defined as one who had ever drunk alcohol but quit drinking the year preceding the 
study. Never drinker was defined as one who claimed not or very seldom to drink any 
alcohol in his or her lifetime. 
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Drug abuse history was defined as histories of illicit drug use, e.g. hallucinogen, 
opioid, cocaine, heroin, ecstasy or other drug use, dependence and abuse (the 
definition is unclear). Data on drug abuse history was collected from patient records 
based on self reports. Alcohol abuse was categorized in the habit of alcohol drinking 
and was not included in this category. 
Performance status of each patient was measured by using Karnofsky 
Performance Score (KPS) (Hollen et al. 1994)，which was collected from the patients' 
records. The KPS is the most widely used tool to assess the functional status of cancer 
patients and was previously shown to have good reliability and validity (Schag et al. 
1984). It is a descriptive, ordinal scale, consisting of 11-point rating scale, which 
ranges from normal functioning (100) to dead (0) (Mor et al. 1984). The KPS has 
been documented to be a significant predictor of length of survival in terminal ill 
cancer patients. For the purpose of this study, the KPS was classified into 3 
categories: 0-40，50-70, and 80-100. The definition of KPS scale is shown in Table 1. 
Patients with the highest KPS at the time of tumor diagnosis have the best survival 
and quality of life over the course of their illness. Good performance status, in general 
was defined as KPS of greater than 70. 
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Table 1 Definition of the rating scale of Karnofsky Performance Status 
KPS scale Meaning 
100 Normal no complaints; no evidence of disease. 
Able to carry on … ， ‘ . 、 . . 
Able to carry on normal activity; minor signs or 
normal activity and 90 ^ » 
symptoms of disease. 
to work; no special 
care needed. 80 Normal activity with effort; some signs or 
symptoms of disease. 
Unable to work; 70 Cares for self; unable to carry on normal activity or 
able to live at home to do active work. 
and care for most ^^ Requires occasional assistance, but is able to care 
personal needs; for most of his personal needs, 
varying amount of Requires considerable assistance and frequent 
assistance needed. ^^ medical care. 
Unable to care for 40 Disabled; requires special care and assistance. 
self, requires ^q Severely disabled; hospital admission is indicated 
equivalent of although death not imminent. 
institutional or ^q Very sick; hospital admission necessary; active 
hospital care; supportive treatment necessary. 
disease may be 10 Moribund; fatal processes progressing rapidly. 
progressing rapidly. q Dead 
(University of Pennsylvania Health System, 2009) 
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4.4.2 Co-morbidity 
Co-morbidity was referred to the occurrence of multiple concurrences of acute or 
chronic diseases, or the occurrences of one or more diseases in addition to an indexed 
disease of lung cancer at or before the date of tissue diagnosis of lung cancer 
(Piccirillo & Costas 2004). 
We reviewed each patient' referral letters, medical records and CMS to obtain 
the co-morbid information. The type and the date of diagnosis for each co-morbid 
condition were recorded and coded according to International Classification of 
Diseases, Revision 9 (ICD-9). The total numbers of co-morbid conditions per 
individual was evaluated and it is named as 'co-morbidity count' (Tammemagi et al. 
2003, Sarfati et al. 2009). 
In order to ensure inter-gender comparability, diseases or conditions related to 
reproductive tract of males and females were not included in the co-morbidity count 
(Tammemagi et al. 2003). These conditions included complication of pregnancy, 
childbirth and the puerperium (ICD: 630 - 679)，diseases of male genital organs (ICD: 
600 - 608), inflammatory diseases of female pelvic organs (ICD: 614-616)，other 
disorders of female genital tract (ICD: 617 - 629). • 
4.4.3 Adverse symptoms 
Adverse symptoms presented by patients included shortness of breath, cough, 
• chest pain, haemoptysis, hoarseness of voice, fever, significant weight loss (defined as 
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weight loss more than 10% of premorbid body weight in 6 months), loss of appetite, 
fatigue and other symptoms reported by patients at the date of tissue diagnosis of lung 
cancer. Presenting sign and symptoms were not treated as co-morbidities because they 
might originate from lung cancer itself, co-morbid conditions or both. 
4.4.4 Disease characteristics 
Disease characteristics included histology of lung cancer, histopathologic 
grading, the stage, and location of tumor. Histological typing was classified according 
to the revised World Health Organization (WHO) classification of lung tumor 
(Brambilla et al. 2001). Six lung cancer histotypes were categorized: squamous cell 
carcinoma, adenocarcinoma, bronchioloalveolar carcinoma, small cell lung cancer, 
other defined histotypes pooled (including large cell and mixed types), and 
bronchogenic carcinoma not otherwise specified. Non-small cell of lung cancer 
included squamous cell carcinoma, adenocarcinoma, bronchioloalveolar carcinoma, 
other defined histotypes pooled (including large cell and mixed types), and 
bronchogenic carcinoma not otherwise specified 
Besides the histologic typing, data about histopathologic grading of the tumour 
was collected. Histopathologic grading of the tumour in this study can be defined as 
grading of cell differentiation. The grading was classified as well differentiated, 
moderately differentiated, poorly differentiated and undifferentiated (Gutman 2005). 
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Tumor staging for non-small cell lung carcinoma was classified according to the 
UICC/ AJCC Tumour-Node-Metastasis (TNM) staging system (Lababede, Meziane & 
Rice 1999). Non-small cell lung carcinomas were classified as stage I，II, III, IV and 
unstaged. Small cell lung carcinomas were classified into limited disease and 
extensive disease using Veteran's Administration staging system (Micke et al. 2002). 
Limited disease was confined to the hemithorax of origin, the mediastinum, or the 
supraclavicular nodes, which can be encompassed within a tolerable radiation therapy 
port. Extensive disease was defined as one had spread beyond the supraclavicular 
areas and was too widespread to be included within the definition of limited disease 
(Micke et al. 2002). 
4.4.5 Baseline laboratory findings 
Each patient's baseline laboratory findings were obtained from medical records, 
including hemoglobin, total leukocyte count, total lymphocyte count, differential 
lymphocyte count, platelet count, total serum protein, serum albumin, and lactate 
dehydrogenase level before treatment. 
4.4.6 Treatment data 
Each patient's treatment data were obtained from medical records, including 
chemotherapy, radiotherapy, surgery, combination of treatments, and other treatment 
method, e.g. Chinese herbal medicine. 
4.4.7 Follow up 
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The study start-date was the date of tissue diagnosis of lung cancer. The study 
exit-date was the date of death, date of loss to follow up, or the study end-date if the 
patients had survived by December 2008. All eligible lung cancer cases were 
followed up to 31st December 2008 to ascertain their vital statuses through a number 
of means, including clinical discharge notes, CMS, Department of Health, and Death 
Registry. For patients who died, information about cause of death was traced through 
Department of Health. For those whose vital status could not be ascertained were 
treated as lost to follow up. 
4.5 Statistical analyses 
All information collected was entered into a database using EpiData 3.1, and 
statistical analyses were performed by using SPSS 15.0 for windows. All p values 
were two tailed and p<0.05 was considered to be significant. Descriptive analysis was 
used to compare the differences of demographic data and clinical characteristics 
between patients with and without co-morbidities by using the Chi-square test for 
categorical variables and Student's t-test for continuous variables. 
Survival time was calculated from the date of tissue diagnosis to the study end 
date. Survival curves between subgroups stratified by the presence of Co-morbidities 
were constructed and compared by the Kaplan-Meier method and the log-rank test. 
Multiple Cox's proportional hazard model with a forward stepwise function was 
applied to evaluate the effect of each index of co-morbidities on mortality from all 
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causes and selected causes, after adjustment of major confounding factors, including 
age, gender, performance status, body mass index, stage and histology of disease, and 
treatment details. Three indices of co-morbidity included in this study were (1) the 
presence of co-morbidity, (2) co-morbidity count, and (3) specific co-morbid disease 
or condition. All the models were repeated for the subgroup of small cell lung cancer 
and non small cell lung cancer, respectively. 
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Chapter 5: Results 
5.1 Description of cohort 
Of 1791 patients (356 females and 1435 males) who had enrolled in 2 
case-control studies between July 2002 and August 2006,465 patients were excluded 
from this study because of ineligible according to the inclusion criteria (Table 2): the 
age of 5 female and 22 male patients were beyond the range of 35-79 years, 84 
patients had cancer history before diagnosis of lung cancer, 210 patients did not have 
confirmed histological diagnosis, 107 patients were confirmed not to be lung cancer 
cases, 20 patients were not the new cases since they were diagnosed more than 3 
months before the date of first seen in clinical oncology department, and 17 patients 
had diagnosed as unknown primary. As a result, a total of 1326 patients (74.03%) 
were retained for further data analyses, as shown in Table 2. 
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Table 2 Eligible and ineligible subjects of a historical cohort of lung cancer 
patients during the period of 2002-2006 
Number Proportion 
Male Female Total 
No. % 
Total subjects recruited 1435 356 1791 100 
Ineligible subjects 
Age < 35 or age >80 22 5 27 • 1.51 
Any evidence of malignancy 59 25 84 4.69 
before diagnosis of lung 
cancer 
Histological confirmation was 166 44 210 11.73 
not available 
Not Ca lung 78 29 107 5.97 
Unknown primary 13 4 17 0.95 
Not new cases 15 5 20 1.12 
Eligible subjects 1082 244 1326 74.04 
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5.2 Baseline characteristics 
Table 3 shows the details of the baseline characteristics for the study 
population. Among 1326 patients included in the study, 1082 (81.6 %) were men and 
244 (18.4 %) were women. The median age of these 1326 patients was 67.57 years 
old with range of 35.36 — 79.75 years (mean 輕 D: 65.43[：9.71). About 60% of the 
patients were at age of 65 or above, and slightly more females aged at 65 years old or 
above. However, the age distribution of male patients did not differ significantly from 
the females. 
Of 1073 (59.9%) patients who had known body mass index at the date of tissue 
diagnosis of lung cancer, 69.2% of them had normal body mass index with a range 
from 18.5 to 25kg/ml Of 939 (52.4%) patients with data on KPS, 608 (64.7%) had 
good performance status (KPS>70). The KPS distribution of male patients did not 
differ markedly from that of the females. Among all 1326 lung cancer patients, more 
than half of them (52%) were current smokers. 945 male patients (87.3%) were ever 
smokers who had smoked in their lifetimes while most female patients (71.7%) were 
never smokers. 656 (60.6%) male current smokers were nearly 4 times as high as that 
of the female smokers. More than 50% of male patients were ever smokers who had 
smoked more than 40 pack-years. Among 1133(63.3%) patients had known alcohol 
drinking status, more than half of them (59.6%) were non drinker. Compared with 
females, males were more prone to be alcohol drinkers and drug abusers (3.8% vs 
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0.4%). 433 (46.4%) males have ever been alcohol drinkers in their lifetimes, while 25 
(12.5%) females have ever been alcohol drinkers. 
Table 4 shows the details of the baseline characteristics for the study population, 
stratified by presence of co-morbidity. Among 1326 patients included in the study, 
798 (60.2%) patients presented co-morbid condition while 528 (39.8%) patients did 
not present any co-morbidity. The mean age of those patients with co-morbid 
condition was statistically higher than those without co-morbid condition. Also, 
compared between patients with and without co-morbid condition, significant greater 
proportion of patients who presented with co-morbid condition was current smoker 
and ever drinker. Furthermore, the performance status of those patient with co-morbid 
condition was much poorer, i.e. the KPS was < 70. 
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Table 3 Baseline characteristics of lung cancer patients by gender 
Variables Male (%) Female f%) p-value 
Total no. of patients 1082 244 
Mean age (S.D.) 65.46(9.5) 65.24(10.8) 0.38 
Age 0.38 
<65 441 (40.8) 92 (37.7) 
>65 641 (59.2) 152 (62.3) 
Bocfy mass index 0.03* 
< 18.5 187 (17.3) 33 (13.5) 
18 .5 -25 615 (56.8) 127(52.0) 
> 2 5 89(8.2) 22(9.0) 
Unknown 191 (17.7) 62(25.4) 
KPS 0.23 
0 - 4 0 3 (0.3) 1 (0.4) 
5 0 - 7 0 276 (25.5) 51 (20.9) 
8 0 - 100 499(46.1) 109(44.7) 
Unknown 304 (28.1) 83 (34.0) 
Smoking status <0.001* 
Never smoker 125 (11.6) 175 (71.7) 
Former smoker 289 (26.7) 23 (9.4) 
Current smoker 656(60.6) 33 (13.5) 
Unknown 12(1.1) 13 (5.3) 
Smoking /pack-year < 0.001* 
Mean (S.D.) 44 (34) 7(19) 
Never smoker 125 (11.6) 175 (71.7) 
<20 100(9.2) 19(7.8) 
2 0 - 4 0 281 (26.0) 24(9.8) • 
>40 545 (50.4) 10 (4.1) 
Unknown 31 (2.9) 16(6.6) 
Alcohol drinking status <0.001* 
Never drinker 500 (53.6) 175 (87.5) 
Ever drinker . 380 (40.7) 24 (12.0) 
Current drinker 53 (5.7) 1 (0.5) 
Drug abuse history <0.01* 
Yes 41 (3.8) 1 (0.4) 
No 1035 (96.2) 243 (99.6) 
KPS: Karnofsky Performance Status , 
* significant result, which the p value is <0.05 
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Table 4 Baseline characteristics of lung cancer patients by the presence of 
co-morbidity 
Variables Presence (Vo) Absence f%) p-value 
Total no. of patients 798 (60.2) 528(39.8) 
Mean age (S.D.) 67.66 (8.56) 62.06(10.35) <0.001* 
Gender 0.17 
Male 661 (82.8) 421 (79.7) 
Female 137 (17.2) 107(20.3) 
Body mass index 0.05 
< 18.5 133 (16.7) 87 (16.5) 
18 .5 -25 426 (53.4) 316(59.8) 
> 2 5 69 (8.6) 42 (8.0) 
Unknown 170 (21.3) 83 (15.7) 
KPS <0.001* . 
< 7 0 235 (29.4) 96(18.2) 
> 7 0 327 (41.0) 281 (53.2) 
Unknown 236 (29.6) 151 (28.6) 
Smoking status <0,001* 
Never smoker 154 (19.3) 143 (27.1) 
Former smoker 237 (29.7) 78 (14.8) 
Current smoker 390(48.9) 299(56.6) 
Unknown 17(2.1) 8(1.5) 
Smoking / pack-year <0.01* 
<20 246 (30.8) 200 (37.9) 
2 0 - 4 0 166(20.8) 128(24.2) 
>40 365 (45.7) 192 (36.4) 
Unknown 21 (2.6) 8(1.5) 
Alcohol drinking status <0.001* 
Never drinker 405 (50.8) 272 (51.5) 
Ever drinker 224 (28.1) 183 (34.7) 
Current drinker 46(5.8) 8(1.5) 
Unknown 123 (15.4) 65 (12.3) 
Drug abuse history , 0.13 
Yes 30 (3.8) 12(2.3) 
No 768 (96.2) 516(97.7) 
KPS: Karnofsky Performance Status 
* significant result, which the p value is <0.05 
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5.3 Symptom presentation 
Table 5 shows the prevalence of symptoms for 1326 lung cancer patients in 
Hong Kong, stratified by the presence of co-morbidity. 1,124 patients (84.8%) 
presented symptoms at the date of first seen in clinical oncology department, but most 
of the symptoms were non-specific, e.g. cough or weight loss. The most common 
signs and symptoms of lung cancer in this study were cough (50.6%), shortness of 
breath/ dyspnoea (29.9%) and weight loss (20.9%). Lung cancer patients were often 
poly-symptomatic (developing multiple symptoms) at the time of diagnosis. In this 
study, among 1,124 patients with symptom presentation at the date of first seen in 
clinical oncology department, 748 patients (66.5%) presented more than 1 symptom. 
Our analysis demonstrated an association between the presence of co-morbidity 
and symptom burden among lung cancer patients. Patients without co-morbid 
condition (87.3%) were more likely to diagnose with adverse symptoms during 
diagnosis than those with co-morbid conditions (83.1%). Among those adverse 
symptoms, cough was reported to be the most common presenting symptom among 
lung cancer patients, regardless of presence of co-morbidity. 
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Table 5 Prevalence of adverse symptoms of 1326 lung cancer patients in Hong 
Kong, stratified by presence of co-morbidity 
Variable Presence (%) Absence (%) p-value 
Absence of symptoms 135 (16.9) 67 (12.7) 0.04* 
Presence of symptoms 663 (83.1) 461 (87.3) 
Pulmonary symptoms 
Cough 391 (49.0) 280(53.0) 0.15 
Haemoptysis 123 (15.4) 87 (16.5) 0.60 
Shortness of breath/ Dyspnoea 248 (31.1) 148 (28.0) 0.24 
Chest pain 130(16.3) 115(21.8) 0.01* 
Hoarseness of voice 62 (7.8) 52 (9.8) 0.19 
Blood stained sputum 71(8.9) 51 (9.7) 0.64 
Other symptoms 
Bone pain 21 (2.6) • 23 (4.4) 0.09 
Clubbing 53 (6.6) 49(9.3) 0.08 • 
Weight loss 174 (21.8) 103 (19.5) 0.31 
Fever 7(0.9) 1(0.2) 0.11 
Loss of appetite 19(2.4) 14 (2.7) 0.76 
Lymph node enlargement 15 (1.9) 19 (3.6) 0.05 
* significant result, which the p value is <0.05 
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5.4 Histological characteristics 
Table 6 shows the histology and tumor characteristics of 1326 lung cancer 
patients. There were 1208 cases (91.1%) of NSCLC and 118 cases of SCLC (8.9%). 
The distribution of histological types of NSCLC was described as follows: 
adenocarcinoma 579 (43.7 %), squamous cell carcinoma 256 (19.3 %)，large cell 
carcinoma 27 (2.0 %), and other types of NSCLC 346 (26.1%). Despite 
adenocarcinoma was the predominant type of histology of lung cancer in both males 
and females, it was more frequently observed in women than in men (62.3% versus 
39.6%; p<0.01). On the other hand, squamous cell carcinoma was more frequent in 
men than in women (21.9% versus 8.2%; pO.Ol). 
Details of staging were available for most of patients. For 1205 patients who 
were diagnosed as NSCLC, 82.3% had known staging information and there was no 
significant difference between males and females. Slightly more females were 
diagnosed as early staged lung cancer, which was defined as stage I or stage II disease, 
whereas slightly more males were diagnosed as advanced staged disease, which was 
defined as stage III and stage lY disease. Nevertheless, there was no statistically 
significant difference between men and women (p=0.46). Separately analysis for 
individual staging were performed, it was found that significantly more females was 
diagnosed as stage IV disease than the males (27.7% vs 35.7%; p=0.01). 
For 115 patients who were diagnosed as SCLC, 52 patients (45.2%) and 53 
patients (46.1%) were diagnosed as limited stage and extensive stage respectively, 
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while 10 male patients (8.7%) had unknown staging information. It seems that more 
females were diagnosed as extensive stage; however, there was no significant 
difference between males and females. 
The lesion was commonly found in both left and right upper lobes. It was found 
that 25.4% of lesions situated in the right upper lobe and 17.3% of lesions was found 
in the left upper lobe, especially for the male patients (p=0.03). 
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Table 6 Histological characteristics of 1,326 lung cancer patients in Hong Kong, 
stratified by the presence of co-morbidity 
Variable Presence (%) Absence (%) p-value 
Small cell carcinoma 0.40 
Limited stage 37 (48.1) 15 (37.5) 
Extensive stage 35 (45.5) 20 (50.0) 
Unknown 5 (6.5) 5 (12.5) 
Non small cell carcinoma 0.56 
Adenocarcinoma 342 (47.4) 237 (48.7) 
Squamous cell carcinoma 164 (22.7) 92 (18.9) 
Large cell carcinoma 16 (2.2) 11 (2.3) 
Other NSCLC 199(27.6) 147 (30.2) 
Staging 0.02 
Stage I 95 (13.2) 57(11.7) 
Stage II 41(5.7) 24 (4.9) 
Stage III 216(30.0) 173 (35.5) 
Stage IV 222 (30.8) 165 (33.9) 
Un-stage 147 (20.4) 68 (14.0) 
Location of tumor 0.59 
Left upper lobe 134(16.8) 95 (18.0) 
Left lower lobe 100(12.5) 53 (10.0) 
Right upper lobe 198 (24.8) 138 (26.1) 
Right middle lobe 38(4.8) 31(5.9) 
Right lower lobe 102(12.8) 50 (9.5) 
Bilateral 30(3.8) 21 (4.0) 
Rt. Lung, unspecified location 104(13.0) 74(14.0) 
Lt. lung, unspecified location 74 (9.3) 54 (10.2) 
Unknown 18(2.3) 12(2.3) 
* significant result, which the p value is <0.05 
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5.5 Treatment characteristics 
Table 7 shows the treatment characteristics of 1326 lung cancer patients in Hong 
Kong. 
Of 1326 patients investigated in this study, 30.5% did not receive any treatment 
and there was no statistically significant difference between males and females in 
receiving any treatment (p = 0.94). 
For 1208 patients diagnosed with non small cell lung cancer, 527 patients 
(43.62%) were treated with single treatment (surgery: 112; chemotherapy: 131; 
radiotherapy: 243; other types of treatment: 41), while 294 patients underwent 
combination of treatments. Compared with male patients, it was found that significant 
more female patients underwent surgical treatment (14.9% versus 7.9%; p<0.001). 
For 118 patients with small cell lung cancer, 27 patients were treated with 
chemotherapy while 8 patients were treated with radiotherapy alone. Only 1 patient 
was treated with herbal medicine. Most of the patients (52.5%) were treated by 
combination of treatments of radiotherapy and chemotherapy. No significant 
difference was observed between male and female patients in receiving treatment. 
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Table 7 Treatment characteristics of 1326 lung cancer patients 
NSCLC SCLC 
Treatment Male Female p-value Male Female p-value 
No treatment 314(32.3) 73 (31.1) 0.72 17(15.6) 1 (11.1) 0.72 
Surgery 77(7.9) 35 (14.9) <0.01 2(1.8) 0 0.68 
Chemotherapy 105 (10.8) 26(11.1) 0.90 26 (23.9) 1 (11.1) 0.38 
Radiotherapy 203 (20.8) 40(17.0) 0.19 7(6.4) 1 (11.1) 0.59 
Other 
29 (3.0) 12(5.1) 0.11 1(0.9) 0(0.0) 0.77 
treatment 
Combination 245 (25.2) 49(20.9) 0.16 56(51.4) 6(66.7) 0.42 
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5.6 Haematological characteristics of study population 
Table 8 shows the haematological characteristics of study population. 
For the haematological profile of the study population, it was found that most of 
patients had missing information about haematological and biochemical information. 
For the patients who had haematological and biochemical information, there was no 
significant difference between males and females in the items of total and differential 
leukocyte count, except for the monocyte count. Significant higher monocyte count 
was observed among male patients than female patients (0.83 vs 0.58, pO.OOOl). 
Also, there was no significant difference between patients with and without co-morbid 
conditions, except for the eosinophils count and the level of lactate dehydrogenase. 
Significant higher eosinophil count (0.24 vs 0.34，p=0.02) and level of lactate 
dehydrogenase (498 vs 580, p=0.03) were observed among patients without 
co-morbidity. 
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Table 8 Haematological characteristics of 1326 lung cancer patients 
No. of patients Mean Std. Deviation 
Hemoglobin concentration /L 536 13.17 1.73 
Red blood cell count * 1OV L 494 4.54 1.41 
Total leukocyte count * 10^/ L 536 10.26 4.54 
White blood cell differential count 
Monocyte *10^/L 519 0.80 0.58 
Eosinophils *109/L 515 0.28 0.52 
Basophils *109/L 515 0.04 0.08 
Neutrophil *10^/L 516 7.35 4.21 
Lymphocyte *109/L 520 1.83 1.26 
Serum albumin g/ L 545 39.10 5.76 
Lactate dehydrogenase lU/ L 30 539.1 263.35 
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5.7 Prevalence of co-morbidity 
Table 9 gives the details about the prevalence of co-morbidities among 1326 
patients. Of 1326 patients studied, 795 (60.2%) had at least one concomitant disease 
or condition, whereas 39.8% of them had no co-morbidity at all. More than half of 
patients (51.7%) had 1-2 co-morbidities. More males had one or more co-morbidity 
than the females (p=0.02). 
With regards to the co-morbid disease or condition classified by major disease 
types according to the ICD-9 classification, the most common major type of 
co-morbid conditions in men were circulatory diseases (ICD: 390 — 459) (31.9%), 
respiratory diseases (ICD: 460-519) (13.2%) and endocrine, nutritional and 
metabolic diseases, and immunity disorders (ICD: 240 - 279) (13.2%); in women, the 
most common major groups of co-morbid conditions were circulatory diseases (ICD: 
390-459) (44.3%), endocrine, nutritional and metabolic diseases, and immunity 
disorders (ICD: 240 - 279) (19.7%) and respiratory diseases (ICD: 460-519) (6.6%). 
More females than males had co-morbid diseases of endocrine, nutritional and 
metabolic diseases, and immunity disorders, but there was no significant gender 
difference. Compared with males, female patients had significantly more co-morbidity ‘ 
of diseases of the musculoskeletal system and connective tissue (5.3% vs. 1.2%) but 
had significantly less co-morbidity of respiratory, digestive, infectious and parasitic 
^ diseases (6.6% vs. 13.2%). 
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With regards to the specific disease type, the most frequent co-morbid diseases 
or conditions in males were hypertension (19.8%), COAD (11.9%) and diabetes 
mellitus (11.2%); while the most frequent co-morbid diseases or conditions in females 
were hypertension (29.9%), diabetes mellitus (13.1%) and ischaemic heart disease 
(13.2%). The prevalence of COAD, old pulmonary tuberculosis, and gastric and 
duodenal ulcer among male patients was significantly higher than the female patients 
(Table 9). 
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Table 9 Prevalence of co-morbidities (ICD-9 classification) of lung cancer 
patients 
Variables Male (%) Female (%) p-value 
Numbers of co-morbidity 0.02 
0 418 (38.8) 107 (43.9) 
1 400 (37.2) 68 (27.9) 
2 2 258 (24.0) 69 (28.3) 
Co-morbidities, by major disease type 
Infectious and parasitic diseases (001-139) 117 (10.9) 9 (3.7) <0.001 
Benign neoplasm (200 - 239) 3 (0.3) I (0.4) 0.82 
Endocrine, nutritional and metabolic diseases 
142(13.2) 48(19.7) 0.18 
and immunity disorders (240-279) 
Mental disorders (290-319) 20 (1.9) 7(2.9) 0.47 
Diseases of the nervous system and sense 
25(2.3) 3(1.2) 0.33 
organs (320-389) 
Diseases of the circulatory system (390-459) 343 (31.9) 108 (44.3) 0.19 
Diseases of the respiratory system (460-519) 142(13.2) 16(6.6) <0.01 
Diseases of the digestive system (520-579) 100 (9.3) 6(2.5) <0.001 
Diseases of the genitourinary system 
(580-629) 8(0.7) 2(0.8) 0.98 
Diseases of the musculoskeletal system and 13 (1.2) 13 (5.3) <0.01 
connective tissue (710-739) 
Congenital anomalies (740-759) 7(0.7) 0 (0.0) 0.18 
Co-morbidities, by specific disease type 
Old pulmonary TB (137.0) 87 (8.1) 6(2.5) <0.01 
Hypertension (401 - 405.9) 213 (19.8) 73 (29.9) 0.09 
CO AD (490-496) 128(11.9) 16(6.6) 0.01 
Diabetes mellitus (249 - 250) 121 (11.2) 32 (13.1) 0.89 
Gastric or duodenal ulcer (530 - 538) 70 (6.5) 5 (2.0) <0.01 ‘ 
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5.8 Overall survival 
After tracing via computerized record and clinical notes, it was found that as at 
31/12/2008, 1105 (83.3%) patients died, 163 (12.3%) patients were still alive and 58 
(4.4%) patients were loss to follow up. The median survival time for the entire cohort 
was 10.79 months (range: 0 - 83.4 months), and the 1- and 2-year overall survival 
rates were 25% and 18% respectively. For NSCLC patients, the median survival time 
was 9.26 months (range: 0 - 83.4 months), and the 1- and 2-year overall survival rates 
were 26% and 19% respectively. For SCLC patients, patients presenting with 
localized disease (i.e, limited stage) had median survival duration of 13.37 months 
while those with extensive stage had median survival duration of 8.59 months. The 1-
and 2-year overall survival rates for SCLC were 15% and 9%, respectively. 
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5.8.1 Univariate and multivariate survival analysis for SCLC patients 
Table 10 shows univariate and multivariate results for survival of 116 SCLC 
patients. 
Univariate analyses showed that the presence of co-morbidity, the Karnofsky 
Performance Status Scale less than 70, and extensive stage were the independent 
factors related to significantly shorter survival of 116 SCLC patients. SCLC patients 
underwent any types of treatment had significantly better prognosis than those did not. 
Results from multivariate Cox's proportional hazard model (forward stepwise) 
demonstrated that the KPS score of less than 70 (hazard ratio=2.06; 95% confidence 
interval: 1.20-3.54)，extensive stage (hazard ratio=2.31 ； 95% confidence interval: 
1.44-3.73), and the absence of treatment (hazard ratio=2.82; 95% confidence interval: 
1.53-5.19) were the independent predictors negatively associated with the survival of 
SCLC patients , while the adverse effect of presence of any co-morbidity became 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.8.2 Univariate and multivariate survival analysis for NSCLC patients 
As shown in Table 11, results from univariate analyses revealed that advancing 
age, performance status^70, stage, body mass index less than 18.5, presence of 
adverse symptoms, ever alcohol drinking status, more advanced stage, tumor location 
at right/bilateral, lack of treatment, and the presence of co-morbidity were 
significantly associated with shorter survival of 1,208 NSCLC patients. Results from 
multivariate Cox's proportional hazard analysis showed that the KPS score of less 
than 70 (HR=1.53; 95% CI: 1.30-1.81)，advanced stage, presence of adverse 
symptoms, (HR=1.44，95%CI: 1.19-1.74), tumor located either on right side or 
bilateral (HR=1.18; 95% CI: 1.03-1.34)，and the absence of treatment (HR=1.65; 95% 
CI: 1.43-1.90) was negatively associated the overall survival of NSCLC patients. 
Patients whose body mass index of 18.5 or greater had significantly better prognosis 
than those with lower BMI. There was a borderline and negative effect of the presence 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.8.3 In-depth analyses for the Impact of co-morbidity on lung cancer 
survival 
For lung cancer with any type of co-morbid conditions, the median survival was 
9 months, which was about 3 months shorter than those without co-morbidities 
(median: 11.83 months). Nevertheless, results from multiple Cox's models did not 
suggest a significantly adverse effect of the presence of any co-morbidity on the 
survival of both SCLC and NSCLC, and instead, only a borderline effect was 
suggested (Table 10 and Table 11). However, simply lumping all types of 
co-morbidity into one category o f any co-morbidity' seems inappropriate since 
heterogeneity may occur for different types of co-morbidity on the effect of survival 
for all lung cancer patients, and the effect may vary across different histological 
subtypes. All these aspects are deserved to be further studied as below. 
Table 12 showed an in-depth analysis for the associations between lung cancer 
survival and major types of co-morbidity according to ICD-9 classification. By using 
univariate analysis, it was found that the presence of any co-morbidity was 
significantly associated with an elevated risk of lung cancer mortality. A positive 
gradient of shorter survival with the increasing co-morbid count was observed among 
SCLC patients, but the dose-response relationship was not clear for NSCLC patients. 
. With regard to major co-morbidity types according to ICD-9 classification, it 




organs (ICD: 320 - 389)，diseases of the respiratory system (ICD: 460 -519) , disease 
of the digestive system (ICD: 520 - 579), disease of the genitourinary system (ICD: 
580 - 629)，congenital anomalies (ICD: 740 - 759)，were significantly associated with 
inferior survival for all lung cancer patients. 
After stratification by histological cell type, NSCLC patients with diseases of the 
nervous system and sense organs (ICD: 320 — 389), disease of the digestive system 
(ICD: 520 - 579), disease of the genitourinary system (ICD: 580 - 629) or 
congenital anomalies (ICD: 740 - 759) had increased hazard ratio. For SCLC patients, 
patients with endocrine, nutritional and metabolic diseases, and immunity disorders 
(ICD: 240 - 279), diseases of the circulatory system (ICD: 390 — 459), diseases of the 
respiratory system (ICD: 460 - 5 1 9 ) or congenital anomalies (ICD: 740 — 759) had 
significantly elevated hazard ratio estimates. 
With regards to the specific disease, NSCLC patients with pre existing gastric 
and duodenal ulcer (ICD: 531 — 535) and peripheral vascular disease (ICD: 443) had 
significantly elevated hazard ratio. 
Table 13 showed an in-depth multivariate analysis of survival for lung cancer 
patients. It was found that the presence of any co-morbidity has significantly elevated 
hazard estimates (HR=1.17, 95%CI: 1.03-1.33) for lung cancer patients after 
adjustment of gender, age, smoking pack years, alcohol drinking status, histology of 




(early-staged vs. advanced-staged), histology (NSCLC vs. SCLC), tumour location, 
treatment; while no positive gradient was observed with the increase numbers of 
co-morbidity count. 
With regard of major co-morbidity types according to ICD-9 classification, in the 
multivariate Cox's proportional hazard model, it was found that 4 categories, 
including diseases of the nervous system and sense organs (HR=1.57, 95%CI: 
1.05-2.33), diseases of the circulatory system (HR=1.17, 95%CI: 1.01-1.36)，diseases 
of the digestive system (HR=1.28, 95%CI: 1.02-1.61) and congenital anomalies 
(HR=3.55, 95%CI: 1.64-7.66), were significantly associated with inferior survival for 
all lung cancer patients. 
After stratification by histological cell type, both NSCLC (HR=2.82, 95%CI: 
1.12-7.12) and SCLC patients (HR=6.75, 95%CI: 1.31-34.75) with congenital 
anomalies (ICD: 740 - 759) had significantly elevated hazard ratio estimates 
With regards to the specific disease，patients with peripheral vascular disease 
(ICD: 443) had significantly elevated hazard ratio for all lung cancers (HR=2.25, 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.8.4 Selected underlying causes of death 
Table 14 shows the selected underlying causes of death for all lung cancer patients. 
During the follow up period of 2002-2009, 1105 patients (83.3%) died. Of these 1105 
patients, the underlying causes of death were successfully traced for 1095 patients 
(99.1%). Most of the patients (96.1%) died of lung cancer, making us impossible to 
perform any meaningful subgroup analysis by underlying cause of death. 
Table 14 Underlying cause of death for lung cancer patients 
Cause of death Frequency Percent 
Lung cancer 1062 96.11 
Tuberculosis of lung 1 0.09 
Other malignancy 11 1.00 
Diseases of the circulatory system 5 0.45 
Diseases of the respiratory system 8 0.73 
Diseases of the digestive system 1 0.09 
External causes 7 0.63 
Unknown cause 10 0.90 
Total 1105 100.00 
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Chapter 6: Discussion 
We found 60.2% of lung cancer patients presented with any co-morbidity at the time 
of diagnosis, and more than 85% of them had at least 2 concomitant diseases. Multiple 
Cox's regression analysis showed that the presence of any co-morbidity or any of these 
pre-existing diseases in the nervous system and sense organs, circulatory system, 
digestive system, and congenital anomalies was associated with a significant shorter 
survival of lung cancer patients. We further found a positive but weak gradient with 
increasing numbers of co-morbidity count for both NSCLC and SCLC. Despite a positive 
relationship of the risk of lung cancer death was suggested with most major types or 
specific co-morbidity for NSCLC or SCLC, only a few had achieved statistical 
significance, suggesting statistical power may not be adequate in doing a subgroup 
analysis. 
6.1 Prognostic factors 
Lung cancer has poor prognosis. For those patients with advanced NSCLC, the 
median overall survival varies from 6 to 12 months (Qi et al. 2009; Lam et al. 1995). 
Long-term survival is largely limited to early stage disease. In this study, the median 
survival of stage I disease was 60 months while those of stage IV disease was only 8 
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months. For the survival of SCLC patients, according to the information provided from 
National Cancer Institute (2009), the median survival for patients diagnosed with limited 
stage and extensive stage small cell lung cancer ranged from 16 to 24 months and 6 to 12 
months respectively. The median survival for our SCLC patients with limited stage and 
extensive stage were 13 months and 8 months respectively, which was consistent with 
that reported by National Cancer Institute (2009). 
Recognition of factors that affect the survival of lung cancer patients is important 
for better treatment and clinical patient management. It is because a clear picture of 
prognostic factors allows proper selection of patients for local, systemic or combined 
therapy in clinical practice. In this study, we found that the stage of disease or extent of 
disease, KPS, BMI，presence of treatment were independently influence the survival rates 
for all lung cancer patients. 
Among tumor-related factors, TNM stage and tumor location have been reported to 
well predict the overall survival for NSCLC patients, while there were no significant 
differences in survival prediction among different histological subtypes (e.g., squamous 
cell carcinogma，adenocarcinoma, etc.) ofNSCLC patients (Goldman 1965; (Goya et al. 
2005). 
The TNM staging or disease extent has long been identified as an important 
prognostic factor for NSCLC or SCLC patients (Pastorino, 2008; van Zandwijk, 1995; 
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Buccheri & Ferrigno, 1994; Birim et al. 2006; Bremnes et al. 2003; Stahel et al. 1991). 
The prognosis of early stage lung cancer is superior to that of the late stage patients, after 
adjustment of other important prognostic factors. Thus, the determination of stage plays 
an important role in the selection of therapeutic strategies and prediction future prognosis 
for lung cancer patients. 
The possible prognostic significance of tumor location was also analyzed in our 
study. It was found that the adjusted hazard ratio was higher in patients whose primary 
tumor was either located in right side or bilateral after taking into account of other factors. 
However, the result was inconsistent with another study (Iwasaki et al. 2007). Iwasaki et 
al. (2007) demonstrated that the 5-year survival rate was lower in patients whose primary 
tumor was located in the left lower lobe. Separate analyses were further performed in the 
subgroups of lung cancer patients with tumor located in right lobe and bilateral lobes and 
elevated hazard ratios retained in the model. The mechanisms of an increased hazard ratio 
for patients whose primary tumor was located in right side has not yet been clear, but it is 
fairly clear for patients with bilateral tumor that were presented as advanced disease with 
a generally poor prognosis. 
Apart from tumor-related factors, patient-related factors may also play an important 
role in predicting survival of patients. In this study, the overall condition of patients, 
including performance status, body mass index and presence of adverse symptoms also 
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played a significant role in determining survival of patients with non small cell lung 
cancer. This finding was consistent with other studies (Birim et al. 2006; Brundage 2002; 
Buccheri 1994; Qin et al. 2008). 
The Karnofsky Performance Status Scale has been widely used to quantify the 
functional status of cancer patients (Younes, 2004). Such scale is regarded as an effective 
tool to assess the general clinical condition of patients at the time of admission to 
hospitals (Younes, 2004). KPS has been reported as a strong and important prognostic 
factor to predict the survival of lung cancer patients (Lilenbaum et. al. 2008; Glare 2005). 
The present study showed that approximately 40% of our patients present with a KPS of 
80% or greater. Similar to the findings of other studies (Gonlugur & Gonlugur 2006), our 
study also demonstrated that KPS was a prognostic factor for lung cancer survival. High 
performance status and no substantial weight loss had been shown to be associated with 
higher survival rates of lung cancer patients if they received induction chemotherapy or 
radiotherapy, or both (Brundage et al. 2002). 
In this study, it was found that NSCLC patients who had body mass index of 18.5 
or greater before treatment had better prognosis. Pre-diagnosis body mass index (BMI) is 
one of the nutritional status markers in cancer patients (Park et al. 2006), which 
represents one of the anthropometric measurements to define nutrition status (Slaviero et 
al. 2003). The World Health Organization defines a BMI of less than 18.5 as underweight 
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to indicate a malnutrition or poor nutritional status, while a BMI greater than 25 is 
considered as overweight and above 30 is considered as obese (World Health 
Organization 2006). Previous studies have shown that underweight patients are more 
likely to suffer more complications, which lead to greater mortality rate, after surgical 
management (Martin-Ucar et al. 2003; Win et al. 2008; Suemitsu et al. 2008). Another 
study has shown that BMI less than 22 kgm'^ was associated with a decreased one year 
survival rate among lung cancer patients (Hurria & Kris 2003). 
Many previous literatures reported that pretreatment symptoms were predictors of 
survival (Martins et al. 2005). A high cumulative symptom burden would be suggestive 
of poor outcome and it is supported by this study. Patients with lung cancer often suffer 
from multiple symptoms. The signs and symptoms presented by patients depend on the 
location of tumor, if local/regional spread, and the effects of metastatic growth (Yoder 
2006). Most of lung cancer patients present with either nonspecific systemic or metastatic 
symptoms, and among which cough is often the presenting and most distressing symptom 
(Mohan et al. 2006; Yoder 2006). In this study, slightly more than half of patients present 
cough during diagnosis. We found an adverse effect of the presence of adverse symptoms ‘ 
including cough on the survival of NSCLC patients. 
6.2 Prevalence of co-morbidity 
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Patients with cancer often have other chronic condition or illness, which is referred 
to as co-morbidities. Lung cancer is strongly associated with age and smoking, and both 
of these factors are associated with co-morbidity. As a result, it is expected that 
co-morbidity is common in lung cancer patients. In this study, 60.2% of patients had at 
least one co-morbid condition at the diagnosis of lung cancer. Compared with previous 
studies, our estimates of co-morbidity was much lower. The prevalence of co-morbidity 
in population based and hospital based (Janssen-Heijnen et al. 1998; Tammemagi et al. 
2004a) lung cancer studies were 66% and 88%, respectively. The difference in the 
prevalence of co-morbidity may be due to different selection criteria of co-morbidity 
among different studies. In our study, the lung cancer patients without prior cancer 
history were included. However, A study conducted in Spain, involving 1121 stage I 
patients who underwent complete resection, found that the presence of previous tumor 
increased the risk of mortality for 45% (95% C.I.: 17% — 79%) at 5 years of survival 
(L鎞ez-Encuentra et al. 2007). Also, In order to ensure inter-gender comparability, 
diseases or conditions relating to reproductive tract of male and female were suggested to 
be excluded from co-morbidity count (Tammemagi et al. 2003). As a result, the 
prevalence of co-morbidity in our study was lower than other studies. 
Circulatory disease was the most prevalent type of co-morbidity in both male and 
female patients in this study. The circulatory disease of this study was classified 
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according to ICD-9 classification. It includes hypertension; ischaemic heart disease, 
including myocardial infarction; cerebrovascular disease, including stroke; peripheral 
vascular disease; rheumatic heart disease; congenital heart disease and cardiomyopathies. 
In this study，34.2% of patients had circulatory disease and 21.7% of patients had 
suffered from hypertension. More female had suffered from circulatory disease or 
hypertension but the difference was not statistically between males and females. The 
results from our study are consistent with other previous studies (Tammemagi et al. 
2004a). It was reported that the incidence of cardiovascular diseases among lung cancer 
patients was between 13% and 23% (Mishra et al. 2009). The high prevalence of 
cardiovascular co-morbidity among lung cancer patients is not surprising because both of 
these co-morbidities were associated with advanced age and smoking (Tammemagi et al. 
2003). In this study, 59.6% of patients were age more than 65 years old, and 47.3% of the 
patients even greater than 70 years old. 
With regards to specific diseases, the prevalence of COAD, old pulmonary 
tuberculosis and gastric and duodenal ulcer among male patients was significantly higher 
than female patients, which might be related to different lifestyles between males and 
females. In this study, more males were tobacco smokers and alcohol drinkers than 
females. Smoking has long been recognized to be strongly associated with numerous 
chronic diseases, including COAD and gastric and duodenal ulcer (Tammemagi et al. 
92 
2004b). In addition to this, alcohol drinking was generally considered as risk factor for 
diseases of the digestive system. Alcohol in large quantities was thought to irritate the 
stomach, leading to an increased susceptibility to Helicobacter pylori (Teyssen & Singer 
2003), and hereafter increased the risk for carcinogenesis of digestive system. 
6.3 Impact of co-morbidity on lung cancer survival 
Co-morbidity is an independent prognostic factor and has been linked to a 
negative survival of cancer patient of different types, such as head and neck, prostate and 
breast cancer (Read et al. 2004; Janssen-Heijnen et al. 2005); however, its prognostic 
effect on lung cancer patients remains controversial. 
We found that number of co-morbidities and some types of co-morbid 
diseases/conditions negatively affected the survival of lung cancer patients, after 
adjustment of stage, treatment and other demographic variables. Results from our study 
were consistent with the findings in some other hospital based studies (Tammemagi et al. 
2004a). Satariano & Silliman (2003) indicated that the presence of co-morbidity would 
diminish the function of vital organs or systems and complicate the treatment and ‘ 
management plan of cancer patients, thus reduced the survival of cancer patients as 
consequences. 
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Previous literature has proposed several methods to measure the occurrences of 
co-morbidity for cancer patients (Piccirillo & Costas 2004). Co-morbidity count is one of 
simple method to evaluate the effect of co-morbidity. The total numbers of 
co-morbidities reflects the general health status of the patient (Limmer et al. 2009). It is 
reported that co-morbidity count is a highly significant predictor of survival of cancer 
patients (Tammemagi et al. 2003; Sarfati et al. 2009). However, it should be noted that 
simple count (i.e., yes vs. no) may be inadequate in assessing the co-morbid conditions of 
cancer patients because it does not consider the heterogeneous seriousness of different 
underlying conditions and the possible multiplicative or synergistic relationships between 
different diseases (Sarfati et al. 2009). 
In accordance with the population based study conducted by Janssen-Heijnen 
(Janssen-Heijnen et al. 2007), our study did not observe a significant association between 
co-morbidity and the survival of SCLC patients after controlling for tumour 
characteristics, treatment and other prognostic factors. However, the impact of 
co-morbidity on SCLC tends to less clear and controversial. Most previous studies 
reported that there was no association between the presence of co-morbidity and survival ‘ 
(Janssen-Heijnen et al. 2007; Shepherd et al. 1994; Ludbrook et al. 2003). There was only 
one study found that the presence of co-morbid count>3 co-morbidities had significant 
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lower response to the treatment and a higher thoracic relapse rate for patients with limited 
stage small cell lung cancer (Shepherd et al. 1994). 
Janssen-Heijnen et al. (2004) reported that many of patients died of lung cancer 
before at risk of dying of other co-morbid condition. In this study, we found about 95% 
of our lung cancer patients died of lung cancer itself. It could be interpreted as chronic 
co-morbid conditions need time to exhibit and reveal their effects, and these effects may 
not be easily observed in aggressive cancer, such as small cell lung cancer (Read et al. 
2004). 
Four categories of co-morbidities, according to ICD-9 classification, including 
diseases of the nervous system and sense organs (ICD: 320 - 389)，diseases of the 
circulatory system (ICD: 390 - 459), diseases of the digestive system (ICD: 520 一 579) 
and congenital anomalies (ICD: 740 - 759) were significantly associated with a reduced 
lung cancer survival, even after adjustment of important prognostic factors such as stage 
and performance status. Coexistent cardiovascular disease has previously reported to 
adversely influence prognosis in cancer as well as complicate its treatment, especially 
among early staged patients undergoing surgical management (Stewart 1999; 
Deppermann 2001, Ambrogi et al. 2003, Pastorino et al. 2008，Birim et al. 2006). 
Cardiovascular disease is therefore regarded as ineligible criteria to be recruited in 
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surgical management or clinical trial (Mir et al. 2009; Rowell & Williams 2001; Semrau 
et al. 2008). 
Diseases of the circulatory system in this study were classified according to ICD-9 
classification, which included hypertension; ischaemic heart disease (including 
myocardial infarction); cerebrovascular disease (including stroke); peripheral vascular 
disease; rheumatic heart disease; congenital heart disease and cardiomyopathies. 
Although we did not observe a significant association between the major type of 
co-morbid condition of'diseases of the circulatory system' and the survival of NSCLC 
patients, a worse survival was found among patients with peripheral vascular disease 
(ICD: 443; HR=2.12, 95%CI:1.19-3.83) after adjustment of stage, treatment status and 
other important prognostic factor. 
Peripheral vascular disease (PVD) refers to any disease or disorder of the 
circulatory system outside of the brain and heart. Compared with previous studies 
(Tammemagi et al. 2003), the prevalence of PVD in this study was much lower. 
Peripheral vascular disease is commonly included in many well established co-morbidity 
scales, e.g. Charlson Co-morbidity Index. The effect of PVD was demonstrated in other 
studies by Duque et al who conducted a prospective study of 605 patients undergoing 
surgery, and found that postoperative complications were more likely to occur among 
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patients with peripheral vascular disease, and an increased the risk of overall mortality 
(OR: 2.83; 950/oCI: 1.04 - 7.67) was observed among this group of patients with PVD 
(Diique et al. 1997). 
Diseases of the digestive system in this study, classified according to ICD-9 
classification, included diseases of oral cavity, salivary gland and jaws; diseases of 
esophagus, stomach and duodenum; diseases of intestine and peritoneum; hernia; and 
diseases of the hepatic. The reason why diseases of the digestive system (ICD: 520 - 579) 
was significantly associated with a reduced lung cancer survival was not really known. It 
may be due to its relationship with indication of chemotherapy. Decline hepatic function 
is always a reason of not receiving chemotherapy. Underlying hepatic disease can alter 
the metabolism and excretion of chemotherapy drugs. This may increase systemic 
toxicity (particularly myelosuppression) or worsening of chemotherapy-induced 
hepatotoxicity (King & Perry 2001). Also, H. pylori induced gastric ulcer was 
hypothesized to be associated with cancer progression. H. pylori might promote secretion 
of gastrin synthesism which in turn induce increased mucosal cell proliferation of 
bronchial epithelium and lead to atrophy and induction of Cyclooxygenase-2 (Roussos et ‘ 
al. 2003). Cyclooxygenase-2 plays an important role in the progression and angiogenesis 
of cancers (Sahin et al. 2009). 
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6.4 Strengths and limitations of this study 
Up to our knowledge, this study is the first study conducted in Hong Kong to 
explore the association between co-morbidity and the survival of lung cancer patients. 
Score e.g. Charlson index was commonly used in previous studies to study the impact of 
comorbidity on survival in cancer patients. However, different comorbid conditions will 
have unique effects. For example, COPD have a major impact on the survival among 
early staged lung cancer patients while renal disease have a major impact among late 
staged cancer patients (Geraci et al. 2007). 
Also, patients were heterogenous in not only tumour characteristics, but also 
demographic characteristics e.g, age and sex, which influence patient preferences for 
treatment and treatment outcomes. A co-morbid condition may interact with these 
characteristics (Geraci et al. 2007). Our database contains relevant clinical information on 
a wide variety of clinical and non-clinical variables such as smoking status, alcohol 
drinking, and co-morbidities, etc. The co-morbid information was gathered thoroughly 
through a review of available referral letters, medical records and computer records, i.e. 
clinical management system (CMS) in this study. Other previous studies collected 
co-morbid information by patients' self-reporting during face-to-face interview, a review 
of medical record or analysis of the administrative database that contains diagnoses using 
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common coding system, e.g. ICD-9 (Piccirillo & Costas 2004). Although every method 
has its own advantages and disadvantages, our approach was considered to be more 
objective compared with other studies in collection of co-morbidity information. 
Evidence showed that coding co-morbidity directly from the medical record tended to 
have more accurate ascertainment of co-morbidity (Malenka et al. 1994). We also 
performed a careful statistical adjustment when investigating the effect of co-morbidities 
by using ‘no co-morbidity' as reference group, which is considered to reflect the true 
effect of co-morbidity on the survival of patients. One previous study adopted 'absence of 
that co-morbidity' (e.g., PVD vs. no PVD) as the reference to study the relationship with 
survival, which would possibly underestimate the effect of that specific co-morbidity on 
lung cancer survival because patients with 'no PVD’ may still have suffered from other 
co-morbid disease or condition (Tammemagi et al. 2003). 
Misclassification of co-morbidity is a possible concern of our study. Co-morbid 
conditions were only included if they has been diagnosed by a physician at the time of 
diagnosis, with a clear temporal relationship with survival outcomes. Patients initially 
seeking doctors were not aware of our research question or co-morbidity definitions. . 
Also, patients usually failed to recognize the importance of co-morbid condition and they 
often focus on their most severe condition (i.e., lung cancer). We believe that 
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misclassification of co-morbidity, if it is present in our study, should be non-differential, 
leading to an underestimation of the association with survival. 
Major selection bias was unlikely because the distributions of lung cancer histology 
in our lung cancer cases and the smoking status of our community referents were fairly 
similar to the general population in Hong Kong (Yu et al, 2006; Tse et al, 2009). 
Interviewer bias and potential differential misclassification on smoking status were also 
unlikely because data from a special group of 64 male and 29 female inpatient referents 
(who had to undergo surgical operations for suspected lung cancer and were handled as 
lung cancer cases during the interviews, but eventually were diagnosed as not suffering 
from lung cancer) showed that the proportion of ever smokers and smoking amount were 
different from those surgically confirmed lung cancer cases，but similar to the community 
referents. In addition, the test-retest reliability for smoking status, age at smoking initiation 
and quitting, the amount, and years since smoking cessation was all excellent for both the 
cases (k or ICC: 0.77-0.95) and the referents (k or ICC: 0.83-0.95). 
Loss to follow-up is generally a concern for a cohort study but it should not a major 
issue of our study. We have tried various means, including traced via Department of health 
and reviewed the record to ascertain patients' final vital status, more than 95% were 
successfully traced and the loss to follow up rate was only 4.4%. We also compare the 
baseline characteristics between those successfully traced and loss to follow-up, and found 
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there were no significant differences in these variables. 
The statistical power is considered to be adequacy in studying the association 
between the presence of any co-morbidity and the survival of all lung cancer patients 
(almost 100%). However, it tends to be low when the individual specific co-morbid 
condition or disease was studied (e.g., hypertension, aneurysm) especially in the 
subgroup of NSCLC and SCLC. We posted this point as our major limitation which 
would be addressed in our future larger studies. 
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Chapter 7: Conclusions 
The prevalence of co-morbidity is high among Chinese lung cancer patients. A 
significant shorter survival of lung cancer patients was associated with the presence of 
any co-morbidity or any of these pre-existing diseases in the nervous system and sense 
organs, circulatory system, digestive system, and congenital anomalies. A positive but 
weak gradient with increasing numbers of co-morbidity count was observed for both 
NSCLC and SCLC. Although a positive relationship was suggested between the risk of 
lung cancer death and the presence of most major types or specific co-morbidity for 
NSCLC or SCLC, only a few had achieved statistical significance, suggesting statistical 
power may not be adequate in doing a subgroup analysis and future larger studies are 
warranted. Nevertheless, our study conveys a clear message that inclusion of 
co-morbidity information would guide a better medical practice and make a proper 
treatment decision, as well as optimize the clinical management for patients with lung 
cancer. 
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Chapter 8: Implications and Recommendations for medial practice 
Lung cancer is a disease of advanced age. With the aging of the population and 
higher prevalence of smoking among lung cancer patients, co-morbidity is expected to be 
continuously common among lung cancer patients. In order to maximize treatment 
efficacy, minimize toxicity, and understand treatment preferences of this patient 
population, we need to put additional efforts to manage lung cancer patients. Apart from 
TNM staging and performance status, other critical factors are also needed to be 
considered. Knowledge of the co-morbidities provides important complementary 
information when evaluating the health status of patients before treatment. Efforts to 
improve survival for lung cancer will need to be directed not only to the management of 
lung cancer, but also optimizing the management of coexisting medical illness. In this 
study, the presence of co-morbidity is an important prognostic factor for lung cancer 
patients. Targeted management on specific individual co-morbidity (i.e. peripheral 
vascular disease) on lung cancer patients would be priori to the improvement of the 
survival of lung cancer patients. Moreover, combination of co-morbidity information 
with other demographic and tumor information can improve prognostic outcomes and 
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